Lipid metabolism reprogramming roles in mantel cell lymphoma growth and survival (Englisch)
- Neue Suche nach: Liang, J.
- Neue Suche nach: Guo, J.
- Neue Suche nach: Du, K.
- Neue Suche nach: Shen, H.
- Neue Suche nach: Yin, H.
- Neue Suche nach: Wu, J.
- Neue Suche nach: Wang, L.
- Neue Suche nach: Li, J.
- Neue Suche nach: Xu, W.
- Neue Suche nach: Liang, J.
- Neue Suche nach: Guo, J.
- Neue Suche nach: Du, K.
- Neue Suche nach: Shen, H.
- Neue Suche nach: Yin, H.
- Neue Suche nach: Wu, J.
- Neue Suche nach: Wang, L.
- Neue Suche nach: Li, J.
- Neue Suche nach: Xu, W.
In:
Hematological Oncology
;
41
;
254
;
2023
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:Lipid metabolism reprogramming roles in mantel cell lymphoma growth and survival
-
Beteiligte:
-
Erschienen in:Hematological Oncology ; 41 ; 254
-
Verlag:
-
Erscheinungsdatum:01.06.2023
-
Format / Umfang:1 pages
-
ISSN:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Englisch
-
Datenquelle:
Inhaltsverzeichnis – Band 41
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 1
-
Issue Information| 2023
- 3
-
Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendationsPassamonti, Francesco / Nicastri, Emanuele / Di Rocco, Alice / Guarini, Attilio / Ibatici, Adalberto / Luminari, Stefano / Mikulska, Malgorzata / Visco, Carlo et al. | 2023
- 4
-
ACKNOWLEDGEMENTS| 2023
- 4
-
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13–17 June, 2023| 2023
- 8
-
SCIENTIFIC PROGRAM (as of May 15, 2023) CONFIDENTIAL| 2023
- 11
-
Advances in positron emission tomography and radiomicsBarrington, Sally F. et al. | 2023
- 16
-
Predictors of clinical evolution of SARS‐CoV‐2 infection in hematological patients: A systematic review and meta‐analysisCarrara, Elena / Razzaboni, Elisa / Azzini, Anna Maria / De Rui, Maria Elena / Pinho Guedes, Mariana Nunes / Gorska, Anna / Giannella, Maddalena / Bussini, Linda / Bartoletti, Michele / Arbizzani, Federica et al. | 2023
- 20
-
Cutaneous T‐cell lymphoma—Focus on some problems, and some solutionsBeltraminelli, Helmut et al. | 2023
- 25
-
Management of primary and secondary CNS lymphomaKhwaja, Jahanzaib / Cwynarski, Kate et al. | 2023
- 26
-
DNA damage accumulation and repair defects in FLT3‐ITD acute myeloid leukemia: Implications for clonal evolution and disease progressionLagunas‐Rangel, Francisco Alejandro et al. | 2023
- 30
-
LESSONS LEARNED FROM THE GENETIC HETEROGENEITY OF LYMPHOID MALIGNANCIESShipp, M. A. et al. | 2023
- 30
-
25 YEARS OF ANTIBODY TREATMENTS FOR LYMPHOMAJohnson, P. M. W. et al. | 2023
- 30
-
ELUCIDATING THE ENIGMATIC PATHOBIOLOGY OF HODGKIN LYMPHOMAKüppers, R. et al. | 2023
- 31
-
FRONTLINE INTENSIFIED ABVD DEMONSTRATES SUPERIOR EFFICACY THAN PET‐ADAPTED ABVD IN ADVANCED HODGKIN LYMPHOMA: THE FIL‐ROUGE PHASE 3 TRIAL BY THE FONDAZIONE ITALIANA LINFOMIPinto, A. / Corazzelli, G. / Evangelista, A. / Patti, C. / De Lorenzo, S. / Re, A. / Merli, F. / Botto, B. / Tarantini, G. / Guarini, A. et al. | 2023
- 33
-
NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826Herrera, A. F. / LeBlanc, M. / Castellino, S. M. / Li, H. / Rutherford, S. C. / Evens, A. M. / Davison, K. / Punnett, A. / Hodgson, D. / Parsons, S. K. et al. | 2023
- 35
-
FOURTH GENERATION HUCART19‐IL18 PRODUCES DURABLE RESPONSES IN LYMPHOMA PATIENTS PREVIOUSLY RELAPSED/REFRACTORY TO ANTI‐CD19 CAR T‐CELL THERAPYSvoboda, J. / Landsburg, D. L. / Chong, E. A. / Barta, S. K. / Nasta, S. D. / Ruella, M. / Hexner, E. O. / Marshall, A. / Leskowitz, R. / Four, M. et al. | 2023
- 36
-
Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approachesSilkenstedt, Elisabeth / Dreyling, Martin et al. | 2023
- 37
-
SINGLE CELL OMICS IN THE STUDY OF B CELL LYMPHOMABasso, K. et al. | 2023
- 37
-
CIRCULATING TUMOR DNA (LIQUID BIOPSY)Rossi, D. et al. | 2023
- 37
-
ABSTRACT INCLUDED IN THE LBA SECTION| 2023
- 38
-
THE TUMOR MICROENVIRONMENT OF HODGKIN LYMPHOMA AT SINGLE CELL RESOLUTIONSteidl, C. G. et al. | 2023
- 38
-
TRAJECTORIES OF LYMPHOMAGENESISNadel, B. et al. | 2023
- 38
-
SUBCLONAL HETEROGENEITY DRIVING PROGRESSION AND TRANSFORMATION IN CHRONIC LYMPHOCYTIC LEUKEMIACampo, E. et al. | 2023
- 39
-
Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphomaDesai, Sanjal H. / Mwangi, Raphael / Smith, Alexandra N. / Maurer, Matthew J. / Farooq, Umar / King, Rebecca L. / Cerhan, James R. / Feldman, Andrew L. / Habermann, Thomas M. / Thompson, Carrie A. et al. | 2023
- 39
-
DIVERSITY OF INTRATUMORAL REGULATORY T CELLS IN B‐CELL NON‐HODGKIN LYMPHOMASpasevska, I. / Sharma, A. / Steen, C. B. / Josefsson, S. E. / Blaker, Y. N. / Kolstad, A. / Rustad, E. H. / Meyer, S. / Chellappa, S. / Kushekhar, K. et al. | 2023
- 40
-
IDENTIFICATION OF GENOMIC BIOMARKERS OF DISEASE PROGRESSION AND SURVIVAL IN NEWLY‐DIAGNOSED PRIMARY CNS LYMPHOMAMo, S. / Geng, H. / Ballapuram, A. / Chen, L. / Lu, M. / Devine, W. P. / Wen, K. W. / Solomon, D. / Rubenstein, J. et al. | 2023
- 41
-
CONSOLIDATIVE HCT‐ASCT IS SUPERIOR TO NON‐MYELOABLATIVE CHEMO‐IMMUNOTHERAPY IN NEWLY‐DIAGNOSED PCNSL ‐ UPDATED RESULTS OF THE RANDOMIZED PHASE III MATRIX/IELSG43 TRIALIllerhaus, G. / Ferreri, A. / Binder, M. / Borchmann, P. / Hasenkamp, J. / Stilgenbauer, S. / Roeth, A. / Weber, T. / Egerer, G. / Ernst, T. et al. | 2023
- 43
-
CAR‐T CELLS RADICALLY MODIFY THE MANAGEMENT OF RELAPSED/REFRACTORY PRIMARY CEREBRAL LYMPHOMAS. REAL LIFE RESULTS OF THE FRENCH LOC NETWORKChoquet, S. / Soussain, C. / Waultier‐Rascalou, A. / Xuan, K. Hoang / Guffroy, B. / Ahle, G. / Barrie, M. / Galicier, L. / Diblasi, R. / Ursu, R. et al. | 2023
- 43
-
Update on follicular lymphomaFriedberg, Jonathan W. et al. | 2023
- 44
-
PHASE 2 STUDY OF IBRUTINIB WITH TEMOZOLOMIDE, ETOPOSIDE, LIPOSOMAL DOXORUBICIN, DEXAMETHASONE, RITUXIMAB (TEDDI‐R) FOR SECONDARY CNS LYMPHOMARoschewski, M. / Simard, J. / Melani, C. / Lakhotia, R. / Phelan, J. D. / Pittaluga, S. / Muppidi, J. R. / Lionakis, M. S. / Peer, C. / Pradhan, A. et al. | 2023
- 46
-
FIVE‐YEAR RESULTS OF A PHASE 2 STUDY OF CNS‐ORIENTED THERAPY WITH R‐CHOP FOR UNTREATED INTRAVASCULAR LARGE B‐CELL LYMPHOMA: FINAL ANALYSIS OF THE PRIMEUR‐IVL STUDYShimada, K. / Yamaguchi, M. / Kuwatsuka, Y. / Matsue, K. / Sato, K. / Kusumoto, S. / Nagai, H. / Takizawa, J. / Fukuhara, N. / Nagafuji, K. et al. | 2023
- 48
-
Post‐transplant lymphoproliferative disease in children, adolescents, and young adultsGross, Thomas G. / Rubinstein, Jeremy D. et al. | 2023
- 48
-
A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS WITH COMPLETE METABOLIC RESPONSE AFTER STANDARD IMMUNOCHEMOTHERAPYDavies, A. J. / Zucca, E. / Ceriani, L. / Kryachok, I. / Ciccone, G. / Botto, B. / Balzarotti, M. / Tucci, A. / Rusconi, C. / Usai, S. V. et al. | 2023
- 50
-
R‐CODOX‐M/R‐IVAC VERSUS DA‐EPOCH‐R IN PATIENTS WITH NEWLY DIAGNOSED HIGH‐RISK BURKITT LYMPHOMA: FINAL RESULTS OF A MULTI‐CENTER RANDOMIZED HOVON/SAKK TRIALChamuleau, M. / Stenner, F. / Chitu, D. / Novak, U. / Minnema, M. / Visser, O. / Stevens, W. / Zenz, T. / van Imhoff, G. / Wu, K. et al. | 2023
- 50
-
Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biasesSoscia, Roberta / Della Starza, Irene / De Novi, Lucia Anna / Ilari, Caterina / Ansuinelli, Michela / Cavalli, Marzia / Bellomarino, Vittorio / Cafforio, Luciana / Di Trani, Mariangela / Cazzaniga, Giovanni et al. | 2023
- 51
-
BIOMARKER‐DRIVEN TREATMENT STRATEGY IN HIGH‐RISK LARGE B‐CELL LYMPHOMA (NLG‐LBC‐06 PHASE II TRIAL): IMPACT OF CTDNA AND TP53 ABERRATIONS ON CLINICAL OUTCOMELeppa, S. / Meriranta, L. / Arffman, M. / Jørgensen, J. / Karjalainen‐Lindsberg, M. / Beiske, K. / Pedersen, M. / Drott, K. / Fluge, Ø. / Jyrkkiö, S. et al. | 2023
- 52
-
PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA‐7 STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAWestin, J. R. / Oluwole, O. O. / Kersten, M. J. / Miklos, D. B. / Perales, M.‐A. / Ghobadi, A. / Rapoport, A. P. / Sureda, A. / Jacobson, C. A. / Farooq, U. et al. | 2023
- 54
-
FOXO1‐RICTOR AXIS INDUCES AKT PHOSPHORYLATION DURING CLL CELL ADAPTATION TO BCR INHIBITORS: IMPLICATIONS FOR COMBINATORIAL THERAPYOndrisova, L. / Seda, V. / Hoferkova, E. / Chiodin, G. / Hlavac, K. / Kostalova, L. / Pavlasova, G. Mladonicka / Filip, D. / Zeni, P. Faria / Oppelt, J. et al. | 2023
- 56
-
IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIALLangerbeins, P. / Robrecht, S. / Nieper, P. / Cramer, P. / Fürstenau, M. / Al‐Sawaf, O. / Fink, A. / Kreuzer, K. / Vehling‐Kaiser, U. / Tausch, E. et al. | 2023
- 57
-
Are we reaching the maximum cure rate for Hodgkin lymphoma?Johnson, Peter W. M. et al. | 2023
- 58
-
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDYAl‐Sawaf, O. / Robrecht, S. / Zhang, C. / Olivieri, S. / Chang, Y. M. / Fink, A. M. / Tausch, E. / Schneider, C. / Ritgen, M. / Kreuzer, K. et al. | 2023
- 60
-
LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): PRIMARY ANALYSIS OF TRANSCEND CLL 004Siddiqi, T. / Maloney, D. G. / Kenderian, S. S. / Brander, D. M. / Dorritie, K. / Soumerai, J. / Riedell, P. A. / Shah, N. N. / Nath, R. / Fakhri, B. et al. | 2023
- 61
-
Exosomal NAMPT from chronic lymphocytic leukemia cells orchestrate monocyte survival and phenotype under endoplasmic reticulum stressNi, Jing / Zhang, Ju / Liu, Jiatao / Fan, Lulu / Lin, Xiao / Yu, Hanqing / Sun, Guoping et al. | 2023
- 62
-
EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROMEFrustaci, A. M. / Montillo, M. / Rossi, D. / Zinzani, P. L. / Motta, M. / Gaidano, G. / Quaresmini, G. / Scarfò, L. / Pietrasanta, D. / Coscia, M. et al. | 2023
- 62
-
The germinal center in the pathogenesis of B cell lymphomasPasqualucci, Laura et al. | 2023
- 63
-
GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS AND HAS A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RICHTER’S TRANSFORMATIONCarlo‐Stella, C. / Hutchings, M. / Offner, F. / Mulvihill, E. / Relf, J. / Byrne, B. / Lundberg, L. / Dickinson, M. et al. | 2023
- 65
-
MINIMAL DISSEMINATED AND MINIMAL RESIDUAL DISEASE IN CHILDHOOD AND ADOLESCENT NON‐HODGKIN LYMPHOMAWoessmann, W. et al. | 2023
- 65
-
PRIMARY MEDIASTINAL B‐CELL LYMPHOMA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTSGiulino Roth, L. et al. | 2023
- 66
-
PHASE 2 KEYNOTE‐667: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH CLASSICAL HODGKIN LYMPHOMA (CHL) WITH SLOW EARLY RESPONSE TO FRONT‐LINE CHEMOTHERAPYVinti, L. / Daw, S. / Alvarez, C. Sabado / Fagioli, F. / Beishuizen, A. / Michel, G. / Moleti, M. L. / Cepelova, M. / Thorwarth, A. / Rigaud, C. et al. | 2023
- 67
-
ANALYSIS TREATMENT OUTCOME OF 46 REFRACTORY/RELAPSED PEDIATRIC MATURE B CELL LYMPHOMA PATIENTS‐MULTI‐CENTER EXPERIENCE FROM CHINAZhang, Y. / Huang, S. / Jin, L. / Yang, J. / Hu, B. / Zheng, C. M. / Zhai, W. X. / Wang, S. H. / Li, F. / Yang, X. et al. | 2023
- 68
-
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH REDUCED‐TOXICITY CONDITIONING FOR PEDIATRIC RELAPSED OR REFRACTORY ALK‐POSITIVE ANAPLASTIC LARGE CELL LYMPHOMAKnörr, F. / Zimmermann, M. / Müller, I. / Bader, P. / Lang, P. / Basu, O. / Burkhardt, B. / Beier, R. / Woessmann, W. et al. | 2023
- 69
-
LANDSCAPE OF DRIVER MUTATIONS AND THEIR CLINICAL IMPACTS IN CHINESE PEDIATRIC PATIENTS WITH MATURE B‐CELL NON‐HODGKIN'S LYMPHOMA AND T‐CELL LYMPHOBLASTIC LYMPHOMAZheng, Q. / Li, Y. / Liu, Y. / Zhang, Y. / Jin, L. / Yang, J. / Huang, S. / Hu, B. / Liu, R. / Liu, W. et al. | 2023
- 69
-
PATTERNS OF PRESENTATION AND OUTCOMES IN STAGE IV HODGKIN LYMPHOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP (COG) AHOD1331 TRIALCasey, D. / McCarten, K. / Pei, Q. / Milgrom, S. / Belsky, J. / Cho, S. / Keller, F. / Punnett, A. / Hoppe, B. / Kelly, K. et al. | 2023
- 70
-
Lymphomas in pregnancyPirosa, Maria Cristina / Peccatori, Fedro Alessandro et al. | 2023
- 71
-
ALK‐POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WITH VARIANT ALK‐FUSION PARTNER: A POPULATION‐BASED ANALYSES OF THE NHL‐BFM STUDY GROUPDamm‐Welk, C. / Luedersen, J. / Stadt, U. zur / Richter, J. / Oschlies, I. / Klapper, W. / Rosenwald, A. / Kalinova, M. / Simonitsch‐Klupp, I. / Siebert, R. et al. | 2023
- 71
-
Long term outcomes of gastric mucosa‐associated lymphoid tissue lymphoma treated with radiotherapy: A multi‐center retrospective cohort studySmith, Clinton D. / Gupta, Sanjiv / Sinn Chin, Yaw / Thompson, Stephen R. et al. | 2023
- 71
-
LUNG STAGING IN PEDIATRIC HODGKIN LYMPHOMA: STAGING EVALUATION & RESPONSE CRITERIA HARMONIZATION FOR CHILDHOOD, ADOLESCENT & YOUNG ADULT HL (SEARCH FOR CAYAHL) CONSENSUSSeelisch, J. / Alazraki, A. L. / Attarbaschi, A. / Beishuizen, A. / Cho, S. / de Alarcon, P. A. / Dieckmann, K. / Drachtman, R. A. / Ehrhardt, M. J. / Georgi, T. et al. | 2023
- 73
-
QUALITY OF LIFE IN PEDIATRIC HIGH‐RISK HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB‐BASED INTENSIVE CHEMOTHERAPY—COMPARISON TO HISTORICAL TREATMENT COHORT AND HEALTHY PEERSFeraco, A. M. / Mandrell, B. / Friedmann, A. / Marks, L. / Li, Y. / Weinstein, H. J. / Link, M. P. / Flerlage, J. E. et al. | 2023
- 75
-
QUANTITATIVE WHOLE‐BODY MRI FOR PREDICTING TREATMENT OUTCOME IN PEDIATRIC PATIENTS WITH AGGRESSIVE NON‐HODGKIN LYMPHOMA UNDERGOING CHIMERIC ANTIGEN RECEPTOR T CELL THERAPYLi, Y. X. / Zhang, Y. H. / Zheng, B. J. / Liu, Y. / Hu, B. / Zhu, Q. et al. | 2023
- 75
-
Reappraisal of the role of radiation therapy in lymphoma treatmentSpecht, Lena et al. | 2023
- 76
-
THE GENETIC SUBTYPES AND THE TUMOR MICROENVIRONMENT SIGNATURES ARE ASSOCIATED WITH DISTINCT OUTCOMES IN PERIPHERAL T‐CELL LYMPHOMASuehara, Y. / Sakamoto, K. / Fujisawa, M. / Fukumoto, K. / Makishima, K. / Suma, S. / Abe, Y. / Sugio, T. / Narita, K. / Nakamura, N. et al. | 2023
- 77
-
ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T‐CELL LYMPHOMA: FINAL ANALYSIS OF THE RO‐CHOP TRIALCamus, V. / Thieblemont, C. / Gaulard, P. / Cheminant, M. / Casasnovas, R. / Ysebaert, L. / Damaj, G. L. / Guidez, S. / Pica, G. M. / Kim, W. S. et al. | 2023
- 78
-
The elderly prognostic index predicts early mortality in older patients with diffuse large B‐cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana LinfomiCencini, Emanuele / Tucci, Alessandra / Puccini, Benedetta / Cavallo, Federica / Luminari, Stefano / Usai, Sara Veronica / Fabbri, Alberto / Pennese, Elsa / Marino, Dario / Zilioli, Vittorio Ruggero et al. | 2023
- 78
-
TARGETED AGENTS COMBINED WITH CHOP COMPARED WITH CHOP AS THE FIRST‐LINE THERAPY FOR PERIPHERAL T‐CELL LYMPHOMA: PRELIMINARY RESULTS FROM A PHASE 2 GUIDANCE‐03 TRIALCai, M. / Cheng, S. / Jing, H. / Cui, G. / Niu, T. / Wang, X. / Shen, J. / Huang, L. / Huang, Y. / Wang, L. et al. | 2023
- 79
-
GOLIDOCITINIB IN TREATING REFRACTORY OR RELAPSED PERIPHERAL T‐CELL LYMPHOMA: PRIMARY ANALYSIS OF THE MULTINATIONAL PIVOTAL STUDY RESULTS (JACKPOT8)Kim, W. / Cai, Q. / Song, Y. / Malpica, L. / Mehta‐Shah, N. / Zhao, W. / Zhou, K. / Wu, J. / Zhang, H. / Ding, K. et al. | 2023
- 80
-
FIRST IN HUMAN STUDY OF AUTO4, A TRBC1‐TRAGETTING CART T CELL THERAPY IN RELAPSED/REFRACTORY TRBC1‐POSITIVE PERIPHERAL T‐CELL LYMPHOMACwynarski, K. / Iacoboni, G. / Tholouili, E. / Menne, T. / Irvine, D. / Balasubramaniam, N. / Wood, L. / Stephens, C. / Shang, J. / Xue, E. et al. | 2023
- 81
-
PHASE 2 STUDY OF ANBAL‐CEL, NOVEL ANTI‐CD19 CAR‐T THERAPY WITH DUAL SILENCING OF PD‐1 AND TIGIT IN RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA ‐ INTERIM ANALYSIS RESULTKim, W. / Kim, S. J. / Yoon, D. H. / Eom, H. / Yang, D. / Yoon, S. E. / Cho, H. / Lee, H. / Jung, J. / Yoon, S. et al. | 2023
- 82
-
POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMAMagen, H. / Fried, S. / Itzhaki, O. / Shem‐Tov, N. / Danylesko, I. / Yerushalmi, R. / Marcus, R. / Shouval, R. / Nevo, L. / Shapira‐Frommer, R. et al. | 2023
- 82
-
Peripheral T‐cell lymphomasBroccoli, Alessandro / Zinzani, Pier Luigi et al. | 2023
- 83
-
OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL)Ramos, C. A. / Quach, D. H. / Lulla, P. D. / Rouce, R. H. / Sharma, S. / Ganesh, H. R. / Nouraee, N. / Briones, Y. D. / Becerra‐Dominguez, L. / Thakkar, S. G. et al. | 2023
- 85
-
DURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501/501A IN PHASE 1 TRIALS OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (R/R LBCL)Locke, F. L. / Lekakis, L. / Eradat, H. / Munoz, J. / Tees, M. / de Vos, S. / Nath, R. / Stevens, D. / Malik, S. / Popplewell, L. et al. | 2023
- 87
-
HIGH EFFICACY AND FAVORABLE SAFETY OF 3RD GENERATION CD20 CAR‐T (MB‐106) FOR OUTPATIENT TREATMENT OF FOLLICULAR LYMPHOMA (FL)—RESULTS OF A SINGLE‐INSTITUTION TRIALShadman, M. / Yeung, C. / Redman, M. / Lee, S. Y. / Lee, D. H. / Qian, D. H. / Ra, S. / Ujjani, C. S. / Dezube, B. J. / Warren, E. H. et al. | 2023
- 88
-
Autologous hematopoietic cell transplantation versus whole‐brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta‐analysisEpperla, Narendranath / Reljic, Tea / Chowdhury, Sayan Mullick / Ferreri, Andrés J. M. / Kumar, Ambuj / Hamadani, Mehdi et al. | 2023
- 88
-
Marginal zone lymphomasZucca, Emanuele / Rossi, Davide / Bertoni, Francesco et al. | 2023
- 88
-
EPIGENETIC BASIS AND THERAPY OF DLBCLMelnick, A. M. et al. | 2023
- 89
-
EPIGENETIC REGULATION OF IMMUNE MICROENVIRONMENT INTERACTIONS IN LYMPHOMAGreen, M. R. et al. | 2023
- 89
-
EPIGENETIC BASIS AND THERAPY OF FOLLICULAR HELPER T‐CELL LYMPHOMASLemonnier, F. et al. | 2023
- 89
-
SUPER‐ENHANCER HYPERMUTATION IN DLBCL: ROLE OF ALTERATIONS IN THE GLUCOCORTICOID RECEPTOR PATHWAYBal, E. / Corinaldesi, C. / Holmes, A. B / Pasqualucci, L. / Basso, K. / Dalla‐Favera, R. et al. | 2023
- 90
-
BASELINE PET RADIOMICS OUTPERFORMS CLINICAL RISK SCORES IN PREDICTING PRIMARY MEDIASTINAL B‐CELL LYMPHOMA OUTCOME: INSIGHTS FROM THE IELSG37 STUDYCeriani, L. / Milan, L. / Cascione, L. / Di Rocco, A. / Kryachok, I. / Davies, A. J. / Stathis, A. / Johnson, P.W.M. / Ciccone, G. / Martelli, M. et al. | 2023
- 91
-
RISK STRATIFICATION OF DLBCL WITH MVED2 SCORE USING INTEGRATIVE HOST ADIPOSE DENSITY AND METABOLIC TUMOR CHARACTERISTICS COMPARED TO OTHER INDEXESThieblemont, C. / Chartier, L. / Vercellino, L. / Deux, J. / Casasnovas, O. / Judet, A. / Baud, V. / Tilly, H. / Cottereau, A. et al. | 2023
- 92
-
Novel agents in relapsed/refractory diffuse large B‐cell lymphomaVarma, Gaurav / Goldstein, Jordan / Advani, Ranjana H. et al. | 2023
- 92
-
BASELINE SUV AND EARLY RESPONSE, BUT NOT MTV, ARE ASSOCIATED WITH OUTCOME IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH NIVOLUMAB IN THE CHECKMATE 205 TRIALBarrington, S. F. / Fischer, B. M. / Kirkwood, A. A. / Grootendorst, D. / Akyol, A. / Ansell, S. M. / Armand, P. / Schwartz, L. H. et al. | 2023
- 93
-
DYNAMICS OF RADIOMIC FEATURES FOLLOWING BRIDGING THERAPY DETERMINE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY OUTCOMEImber, B. S. / Silverman, E. A. / Leithner, D. / Hubbeling, H. / Shah, G. L. / Fregonese, B. / Sanin, B. W. / Tomas, A. A. / Parascondola, A. / Saldia, A. et al. | 2023
- 94
-
RADIOMICS REFLECTING BOTH TUMOR AND HOST FEATURES IMPROVES OUTCOME PREDICTION IN FOLLICULAR LYMPHOMARebaud, L. / Capobianco, N. / Spottiswoode, B. / Cottereau, A. / Trotman, J. / Feugier, P. / Nastoupil, L. J. / Bachy, E. / Flinn, I. W. / Haioun, C. et al. | 2023
- 95
-
GENETICALLY DISTINCT PATHOGENESIS OF EPSTEIN‐BARR VIRUS (EBV)‐POSITIVE VERSUS EBV‐NEGATIVE CLASSICAL HODGKIN (CHL) LYMPHOMAGomez, K. / Schiavoni, G. / Nam, Y. / Reynier, J. / Khamnei, C. / Aitken, M. / van Noesel, C. / Falini, B. / Pasqualucci, L. / Rabadan, R. et al. | 2023
- 96
-
DISTINCT HODGKIN LYMPHOMA SUBTYPES IDENTIFIED BY NONINVASIVE GENOMIC PROFILINGAlig, S. K. / Esfahani, M. Shahrokh / Garofalo, A. / Li, M. Y. / Rossi, C. / Adams, R. / Binkley, M. S. / Jin, M. C. / Olsen, M. / Telenius, A. et al. | 2023
- 97
-
Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab eraVassilakopoulos, Theodoros P. / Panitsas, Fotios / Mellios, Zois / Apostolidis, John / Michael, Michalis / Gurion, Ronit / Ferhanoglu, Burhan / Hatzimichael, Eleftheria / Karakatsanis, Stamatios / Dimou, Maria et al. | 2023
- 99
-
DUAL TARGETING OF HODGKIN’S LYMPHOMA BY ANTI‐CD30 CAR‐T CELLS CO‐TRANSDUCED WITH AN ANTI‐PDL1 COSTIMULATORY RECEPTOR TO OVERCOME THE IMMUNOSUPPRESSIVE MICROENVIRONMENTPerriello, V. M. / Martarelli, N. / Gentili, M. / Capurro, M. / Marra, A. / Erol, G. / Gobbi, M. / Tiacci, E. / Falini, B. et al. | 2023
- 100
-
THE PROGNOSTIC IMPACT OF CLINICAL FACTORS AND IMMUNOARCHITECTURAL PATTERNS FOR NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA: AN INTERNATIONAL STUDY BY GLOWBinkley, M. S. / Flerlage, J. E / Borchmann, P. / Fuchs, M. / Hartmann, S. / Eich, H. T. / Savage, K. J. / Lo, A. / Skinnider, B. / Akhtar, S. et al. | 2023
- 102
-
MARGINAL ZONE LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (MZL‐IPI): A PROGNOSTIC SCORE FOR THE ENTIRE SPECTRUM OF MARGINAL ZONE LYMPHOMAS. A FIL AND SPORE‐MER STUDYLuminari, S. / Bommier, C. / Fabbri, N. / Nizzoli, M. E. / Maurer, M. J. / Tarantino, V. / Ferrero, S. / Rattotti, S. / Merli, M. / Ferrari, A. et al. | 2023
- 103
-
STAGING FDG‐AVIDITY IN EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL) BY DISEASE LOCATIONAlderuccio, J. P. / Saul, E. Edelman / Stanchina, M. / Sassi, R. Hennemann / Zhao, W. / Moskowitz, C. / Reis, I. / Kuker, R. / Lossos, I. / Polar, M. et al. | 2023
- 104
-
RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS: PLANNED SUBSET ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDYThieblemont, C. / Lamy, T. / Tani, M. / Krzisch, D. / Reda, G. / Tedeschi, A. / Usai, S. V. / Guarini, A. / Bijou, F. / Stathis, A. et al. | 2023
- 106
-
THE IELSG39 TRIAL: EFFICACY OF FIRST‐LINE CHLAMYDIA PSITTACI ERADICATION WITH A SIX‐MONTH REGIMEN OF DOXYCYCLINE IN PATIENTS WITH STAGE‐I MALT LYMPHOMA OF THE OCULAR ADNEXAEFerreri, A. J. M. / Sassone, M. C. / Cangi, M. G. / Magliacane, G. / Zanussi, S. / Marino, F. / Flospergher, E. / Vicari, N. / Bongiovanni, L. / Cin, E. Dal et al. | 2023
- 107
-
The evolving therapy of DLBCL: Bispecific antibodiesHutchings, Martin et al. | 2023
- 107
-
IMMUNOTHERAPY ALONE VERSUS CHEMOIMMUNOTHERAPY AS FIRST‐LINE TREATMENT OF MARGINAL ZONE LYMPHOMA (MZL): A REAL‐WORLD ANALYSISOlszewski, A. J. / Epperla, N. / Chihara, D. / Ollila, T. et al. | 2023
- 108
-
A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphomaCarlo‐Stella, Carmelo / Zinzani, Pier Luigi / Sureda, Anna / Araújo, Luis / Casasnovas, Olivier / Carpio, Cecilia / Yeh, Su‐Peng / Bouabdallah, Krimo / Cartron, Guillaume / Kim, Won Seog et al. | 2023
- 108
-
BTG2 SUPER‐ENHANCER MUTATIONS DISRUPT TFAP4 BINDING AND DYSREGULATE BTG2 EXPRESSION IN DIFFUSE LARGE B‐CELL LYMPHOMABal, E. / De Simone, P. / Holmes, A. B. / Hilton, L. / Basso, K. / Soni, R. K. / Morin, R. D. / Dalla‐Favera, R. / Pasqualucci, L. et al. | 2023
- 108
-
CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY FOLLICULAR HELPER T‐CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDYLoyaux, R. / Sako, N. / Quang, V. Tran / Bachy, E. / Morschhauser, F. / Cartron, G. / Gressin, R. / Daguindau, N. / Le Gouill, S. / Wolfromm, A. et al. | 2023
- 110
-
MOLECULAR CHARACTERIZATION CONTRIBUTES TO DIAGNOSIS AND PREDICTS OUTCOME IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMAS: A LYSA STUDYCamus, V. / Viailly, P. / Sesques, P. / Drieux, F. / Veresezan, E. / Haioun, C. / Durot, E. / Patey, M. / Rossi, C. / Martin, L. et al. | 2023
- 111
-
GENE EXPRESSION PROFILING OF T(14;18)‐NEGATIVE CD23+ FOLLICLE CENTER LYMPHOMA DEMONSTRATES ACTIVATION OF THE IL4/JAK/STAT6 PATHWAY AND A ROLE IN ITS PATHOGENESISSchade, T. / Nann, D. / Rau, A. / Chott, A. / Leoncini, L. / Fend, F. / Salaverria, I. / Campo, E. / Jaffe, E. / Bonzheim, I. et al. | 2023
- 112
-
CAR T‐cell therapy in large B cell lymphomaBoardman, Alexander P. / Salles, Gilles et al. | 2023
- 112
-
IMMUNOGLOBULIN CLASS DICTATES TRANSFORMATION TRAJECTORY AND BCR STATUS OF MYC/BCL2 DOUBLE‐HIT LYMPHOMA: BIOLOGY AND CLINICAL IMPLICATIONSCasola, S. / Sindaco, P. / Lonardi, S. / Zanardi, F. / Neuman, H. / Lorenzi, L. / Balzarini, P. / Morello, G. / Varano, G. / Bugatti, M. et al. | 2023
- 113
-
1998–2023 TWENTY‐FIVE YEARS OF COMMITMENT TO IMPROVING OUR UNDERSTANDING OF LYMPHOMAZucca, E. et al. | 2023
- 113
-
INTRODUCTION OF LYMPHOMA DATABASE OF NATIONAL HEALTH COMMISSION OF THE PEOPLE'S REPUBLIC OF CHINALiu, W. / Song, Y. / Zhu, J. / Ma, J. / Ma, Z. / Yang, A. et al. | 2023
- 114
-
SMART START WITH TISLELIZUMAB AS THE FRONT‐LINE TREATMENT IN PATIENTS WITH HIGH‐RISK STAGE IIB AND ADVANCED‐STAGE CLASSICAL HODGKIN LYMPHOMAWang, Y. / Yang, H. / Sun, P. / Nie, M. / Li, J. / Cao, J. / Huang, Y. / Li, Z. et al. | 2023
- 115
-
ROLE OF CHECKPOINT INHIBITION IN GERMANYBorchmann, P. et al. | 2023
- 115
-
NEW DRUG DEVELOPMENT IN LYMPHOMA OF CHINA IS GOING GLOBALZhou, K. et al. | 2023
- 116
-
NEW TRENDS IN LYMPHOMA TREATMENT IN WESTERN COUNTRIESZinzani, P. L. et al. | 2023
- 116
-
A “FUNCTIONAL CURE” MAY BE ACHIEVABLE IN A SUBSET OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH CHEMOIMMUNOTHERAPY: 15‐YEAR FOLLOW‐UP OF PHASE III SWOG‐S0016Shadman, M. / Li, H. / Rimsza, L. / Leonard, J. P. / Kaminski, M. S / Spier, C. M / Gopal, A. K / Dakhil, S. / LeBlanc, M. / Smith, S. M. et al. | 2023
- 117
-
SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPYØstenstad, B. / Pirosa, M. C. / Schär, S. / Brodtkorb, M. / Wahlin, B. E. / Hernberg, M. / Pedersen, M. / Stathis, A. / Zander, T. / Novak, U. et al. | 2023
- 119
-
ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDYZinzani, P. L. / Mayer, J. / Trotman, J. / Bijou, F. / de Oliveira, A. C. / Song, Y. / Zhang, Q. / Merli, M. / Bouabdallah, K. / Ganly, P. S. et al. | 2023
- 119
-
Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemiaChen, Shih‐Shih / Chiorazzi, Nicholas et al. | 2023
- 120
-
Effects of the BTN162b2 mRNA COVID‐19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemiaFiorcari, Stefania / Atene, Claudio Giacinto / Maffei, Rossana / Mesini, Nicolò / Debbia, Giulia / Colasante, Corrado / Pozzi, Stefano / Barbieri, Emiliano / Maccaferri, Monica / Leonardi, Giovanna et al. | 2023
- 121
-
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2Novelli, S. / Luminari, S. / Taszner, M. / Cho, S. / Le Gouill, S. / Poon, M. / Villasboas, J. C. / Champion, R. / Bachy, E. / Guidez, S. et al. | 2023
- 122
-
MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDYSehn, L. H. / Bartlett, N. L. / Matasar, M. / Schuster, S. J. / Assouline, S. / Giri, P. / Kuruvilla, J. / Shadman, M. / Cheah, C. Y. / Fay, K. et al. | 2023
- 125
-
EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUSBelada, D. / Falchi, L. / Leppä, S. / Vermaat, J. S. / Holte, H. / Hutchings, M. / Lugtenburg, P. / de Vos, S. / Abrisqueta, P. / Nijland, M. et al. | 2023
- 127
-
DOES IT MATTER HOW WE NAME LYMPHOMAS?Armitage, J. O. et al. | 2023
- 127
-
HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 T‐CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDYCho, S. / Nair, R. / Jacobs, R. / Devata, S. / Gaballa, S. / Yoon, D. H. / Stevens, D. A. / Kim, J. S. / Shah, N. N. / Brennan, D. M. et al. | 2023
- 128
-
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohortMerli, Michele / Ferrarini, Isacco / Merli, Francesco / Busca, Alessandro / Mina, Roberto / Falini, Brunangelo / Bruna, Riccardo / Cairoli, Roberto / Marchetti, Monia / Romano, Alessandra et al. | 2023
- 129
-
PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)Danilov, A. / Gregory, G. P. / Morschhauser, F. / Cheah, C. Y. / Shah, H. / Jurczak, W. / Olabode, D. / Meyer, S. / Yoon, J. L. / Arduini, S. et al. | 2023
- 129
-
First line therapy of CLLHallek, Michael et al. | 2023
- 131
-
PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)Hertzberg, M. / Kalac, M. / Cheah, C. Y. / Ribrag, V. / Abrisqueta, P. / Opat, S. / Bachy, E. / Ysebaert, L. / Qiu, L. / Yi, S. et al. | 2023
- 132
-
ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITOR SHR2554 IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL): UPDATED OUTCOMES FROM THE FIRST‐IN‐HUMAN PHASE 1 STUDYSong, Y. / Zhu, J. / Jin, Z. / Li, Z. / Liu, Y. / Li, L. / He, C. / Su, H. / Zhou, H. / Li, K. et al. | 2023
- 134
-
OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)Michot, J. M. / Chavez, J. / Carpio, C. / Bachy, E. / Ferrari, S. / Morschhauser, F. / Jørgensen, J. M. / Cordoba, R. / Bories, P. / Patah, P. et al. | 2023
- 136
-
Approach to relapsed CLL including Richter TransformationSeymour, John F. et al. | 2023
- 136
-
COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAHutchings, M. / Dickinson, M. / Carlo‐Stella, C. / Morschhauser, F. / Bosch, F. / Gritti, G. / Townsend, W. / Bartlett, N. L. / Cartron, G. / Ghesquieres, H. et al. | 2023
- 138
-
GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMAHutchings, M. / Avigdor, A. / Sureda, A. / Terol, M. J. / Bosch, F. / Corradini, P. / Larsen, T. Stauffer / Domínguez, A. Rueda / Skarbnik, A. / Jørgensen, J. et al. | 2023
- 139
-
The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor‐based regimens as induction treatment: A real‐world analysisChen, Haimin / Zhou, Nian / Hu, Xiaohua / Wang, Dongjiao / Wei, Wei / Peng, Rong / Chen, Xiaoling / Shi, Haotian / Wu, Lixia / Yu, Wenjun et al. | 2023
- 141
-
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2Poon, M. / Walewski, J. / Kim, T. M. / Cho, S. / Jarque, I. / Iskierka‐Jażdżewska, E. / Prince, H. M. / Oh, S. Y. / Lim, F. / Carpio, C. et al. | 2023
- 142
-
SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: LONGER FOLLOW‐UP FROM THE PIVOTAL EPCORE NHL‐1 TRIALThieblemont, C. / Karimi, Y. / Jurczak, W. / Cheah, C. Y. / Clausen, M. R. / Cunningham, D. / Do, Y. R. / Lewis, D. J. / Gasiorowski, R. / Kim, T. M. et al. | 2023
- 144
-
GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDYDickinson, M. / Carlo‐Stella, C. / Morschhauser, F. / Falchi, L. / Bachy, E. / Cartron, G. / Khan, C. / Tani, M. / Martinez‐Lopez, J. / Bartlett, N. et al. | 2023
- 147
-
BISPECIFIC ANTI‐CD20/19 CAR‐T—ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL—INTERIM ANALYSIS RESULTS OF DALY‐II‐USA STUDYUlrickson, M. / Miklos, D. B. / Maziarz, R. T / Jacobson, C. / Isufi, I. / Ghosh, M. / Perales, M. / Lunning, M. / Hardy, N. M. / Wijatyk, A. et al. | 2023
- 147
-
AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDYHouot, R. / Bachy, E. / Cartron, G. / Gros, F. / Morschhauser, F. / Oberic, L. / Gastinne, T. / Feugier, P. / Dulery, R. / Thieblemont, C. et al. | 2023
- 147
-
Intensified conditioning regimens improved disease‐free survival and engraftment after unrelated single‐unit cord blood transplantation but not after matched sibling or matched unrelated donor allogeneic hematopoietic cell transplantationKonuma, Takaaki / Kanda, Junya / Uchida, Naoyuki / Nishijima, Akihiko / Tanaka, Masatsugu / Ozawa, Yukiyasu / Sawa, Masashi / Onizuka, Makoto / Ota, Shuichi / Maruyama, Yumiko et al. | 2023
- 148
-
FIVE‐YEAR UPDATE OF THE FIRST‐LINE IMCL‐2015 GELTAMO STUDY. PROLONGED MOLECULAR AND CLINICAL RESPONSES WERE OBSERVED AFTER MRD‐DRIVEN IBRUTINIB DISCONTINUATIONGiné, E. / Medina‐Herrera, A. / Cruz, F. de la / Ubieto, A. Jiménez / Jiménez, J. López / García‐ Sancho, A. Martín / Terol, M J. / Barca, E. González / Casanova, M. / Fuente, A. de la et al. | 2023
- 150
-
ACALABRUTINIB WITH RITUXIMAB AS FIRST‐LINE THERAPY FOR OLDER PATIENTS WITH MANTLE CELL LYMPHOMA—A PHASE II CLINICAL TRIALJain, P. / Ok, C. y. / Fetooh, A. / Nastoupil, L. / Westin, J. / Hill, H. A. / Nair, R. / Iyer, S. P. / Steiner, R. E. / Lee, H. J. et al. | 2023
- 151
-
VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.Sarkozy, C. / Thieblemont, C. / Oberic, L. / Moreau, A. / Bouabdallah, K. / Damaj, G. / Gastine, T. / Ribrag, V. / Casasnovas, O. / Haioun, C. et al. | 2023
- 152
-
IBRUTINIB‐RITUXIMAB AND VENETOCLAX (IRV) FOLLOWED BY RISK‐STRATIFIED R‐HYPERCVAD/MTX IN YOUNG PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA—PHASE‐II WINDOW‐2 TRIALWang, M. L. / Lee, H. J. / Fetooh, A. / Nair, R. / Ok, C. Y. / Hill, H. A. / Iyer, S. P / Steiner, R. E. / Westin, J. / Nastoupil, L. et al. | 2023
- 153
-
PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENTCheah, C. Y. / Shah, N. N. / Jurczak, W. / Zinzani, P. Luigi / Eyre, T. A. / Ujjani, C. S. / Izutsu, K. / Ma, S. / Flinn, I. / Alencar, A. J. et al. | 2023
- 156
-
OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI‐INSTITUTION RETROSPECTIVE ANALYSISMessmer, M. / Stack, A. / Deng, M. / Handorf, E. / Kapoor, N. / Sawalha, Y. / Bock, A. M. / Wang, Y. / Graf, K. / Greenwell, B. et al. | 2023
- 158
-
CORRELATION BETWEEN PROGRESSION‐FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM GHSG TRIALSBröckelmann, P. J. / Müller, H. / Gillessen, S. / Jacob, A. / Momotow, J. / Damaschin, C. / Ferdinandus, J. / Yang, X. / Fuchs, M. / Kobe, C. et al. | 2023
- 159
-
Co‐mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndromeRen, Yanling / Lang, Wei / Mei, Chen / Luo, Yingwan / Ye, Li / Wang, Lu / Zhou, Xinping / Xu, Gaixiang / Ma, Liya / Jin, Jie et al. | 2023
- 159
-
EARLY FDG‐PET ADAPTED TREATMENT OF LIMITED STAGE HODGKIN LYMPHOMA (HL): 10Y LONG TERM FOLLOW‐UP ANALYSIS OF THE RANDOMIZED INTERGROUP EORTC/LYSA/FIL H10 TRIALFederico, M. / Fortpied, C. / Stepanishyna, Y. / Gotti, M. / van der Maazen, R. / Amorin, S. / Re, A. / Plattel, W. / Lazarovici, J. / Merli, F. et al. | 2023
- 160
-
PEMBROLIZUMAB AS FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD‐INELIGIBLE PATIENTS, ALLOWS SUBSEQUENT THERAPY, AND GIVES ADEQUATE SURVIVAL.Dickinson, M. J. / Trotman, J. / Berkahn, L. / Butler, J. / Bressel, M. / Neeson, P. / Minson, A. et al. | 2023
- 161
-
PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DACARBAZINE (N‐AVD) AS FRONTLINE THERAPY IN OLDER ADULTS WITH HODGKIN LYMPHOMATorka, P. / Feldman, T. / Savage, K. / Ganesan, N. / Hancock, H. / Davey, T. / Perez, L. / Santarosa, A. / Subzwari, S. / Capadona, C. et al. | 2023
- 162
-
AVELUMAB MONOTHERAPY FOLLOWED BY A PET ADAPTED CHEMOTHERAPY APPROACH IN THE FIRST LINE TREATMENT OF CLASSICAL HODGKIN LYMPHOMA: INITIAL RESULTS FROM THE AVENUE WINDOW STUDYCollins, G. P. / Hawkes, E. A. / Kirkwood, A. A. / Clifton‐Hadley, L. / Tyson, C. / Barsoum, E. / Pettengell, R. / Medd, P. G. / McKay, P. / Miall, F. et al. | 2023
- 163
-
FAVEZELIMAB PLUS PEMBROLIZUMAB IN ANTI–PD‐1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL): ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMABArmand, P. / Zinzani, P. L. / Timmerman, J. / Johnson, N. / Lavie, D. / Thiagarajan, K. / Topp, B. / Pillai, P. / Herrera, A. F. et al. | 2023
- 165
-
SAKK 38/19: ASSESSING A CTDNA AND PET‐ORIENTED THERAPY IN PATIENTS WITH DLBCL. A MULTICENTER, OPEN‐LABEL, PHASE II TRIALStathis, A. / Hitz, F. / Schär, S. / Novak, U. / Fischer, N. / Mey, U. / Gritti, G. / Zander, T. / Lang, N. / Cairoli, A. et al. | 2023
- 166
-
REMODL‐A: A RANDOMISED PHASE II EVALUATION OF MOLECULAR GUIDED THERAPY FOR DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) WITH ACALABRUTINIB — ONGOING TRIALRadhakrishnan, V. S. / Stanton, L. / Caddy, J. / Keyworth, N. / Saunders, G. / Barrans, S. / Rafferty, J. / Joyce, T. / Collins, G. P. / Barrington, S. et al. | 2023
- 167
-
Brentuximab Vedotin‐Nivolumab alone and then with Rituximab‐Cyclophosphamide‐Doxorubicin‐Prednisone as Frontline Therapy of Primary Mediastinal Large B‐cell LymphomaSteiner, R. E. / Strati, P. / Flowers, C. R. / Neelapu, S. S. / Green, M. / Nastoupil, L. J. / Hagemeister, F. B. / Feng, L. / Ahmed, S. / Nair, R. et al. | 2023
- 167
-
Prognostic factors in patients with bone marrow hemophagocytosis and its association with hematologic malignanciesJiang, Jing‐Gu / Liu, Chia‐Jen / Yeh, Chiu‐Mei / Yang, Ching‐Fen / Liu, Yao‐Chung / Wang, Hao‐Yuan / Ko, Po‐Shen / Chen, Po‐Min / Yu, Yuan‐Bin / Gau, Jyh‐Pyng et al. | 2023
- 168
-
MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI‐CD20 VERSUS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMASehn, L. / Sarkozy, C. / Song, Y. / Salar, A. / Trotman, J. / Zinzani, P. L. / Zhang, J. / Zhang, W. / Fustier, P. / Delarue, R. et al. | 2023
- 170
-
SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAPavlovsky, A. / Westin, J. / Olszewski, A. J / Fogliatto, L. / Kim, W. S. / Shin, H. / Leão, D. / Jeon, Y. / Norasetthada, L. / Rego, E. et al. | 2023
- 171
-
ZUMA‐23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST‐LINE THERAPY IN PATIENTS WITH HIGH‐RISK LARGE B‐CELL LYMPHOMAWestin, J. / Jacobson, C. A. / Chavez, J. C. / Sureda, A. / Morschhauser, F. / Glaß, B. / Dickinson, M. / Davies, A. / Flinn, I. W. / Maloney, D. G. et al. | 2023
- 174
-
MOLECULAR CLUSTERING ON CTDNA IMPROVES THE PROGNOSTIC STRATIFICATION OF DLBCL PATIENTS COMPARED TO CTDNA LEVELSMoia, R. / Talotta, D. / Dondolin, R. / Almasri, M. / Cosentino, C. / Bruna, R. / Della Starza, I. / Soscia, R. / Bruscaggin, A. / Di Bergamo, L. Terzi et al. | 2023
- 175
-
CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDYHerrera, A. F. / Tracy, S. / Sehn, L. H. / Jardin, F. / Lenz, G. / Trněný, M. / Salles, G. / Flowers, C. R. / Tilly, H. / Sharman, J. P. et al. | 2023
- 177
-
MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALSRoschewski, M. / Kurtz, D. M. / Westin, J. / Lynch, R. C. / Alig, S. K. / Macaulay, C. / Kuffer, C. / Hogan, G. J. / Schultz, A. / Close, S. et al. | 2023
- 178
-
Competitive evolved sub‐clonal BCR::ABL1 and novel MSI2::PC fusion genes in myelodysplastic syndrome with isolated del(5q)Zhang, Yanqing / Liu, Yang / Wang, Tong / Wang, Hui / Chen, Xue / Cao, Panxiang / Ma, Xiaoli / Liu, Mingyue / Xu, Ping / Bi, Hailiang et al. | 2023
- 179
-
EARLY CTDNA CLEARANCE AFTER CAR T‐CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B‐CELL LYMPHOMA : RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDYDelfau‐Larue, M. / Viailly, P. / Cartron, G. / Morschhauser, F. / Gros, F. / Gastinne, T. / Oberic, L. / Bachy, E. / Dulery, R. / Feugier, P. et al. | 2023
- 181
-
CELL‐FREE DNA KINETICS DECIPHER POTENTIAL MECHANISMS OF ACTION OF IBRUTINIB COMBINATION THERAPY IN MANTLE CELL LYMPHOMA (MCL)Khouja, M. / Genuardi, E. / Ferrero, S. / Alessandria, B. / Verhagen, O. J. / Homburg, C. / van der Velden, V. H. / Gameiro, P. / Sanz, R. García / Herrera, A. Medina et al. | 2023
- 182
-
Association of cesarean section with risk of childhood leukemia: A meta‐analysis from an observational studyYang, Yingzhu / Yu, Chiyuan / Fu, Rongrong / Xia, Shishan / Ni, Haixiang / He, Yujing / Zhu, Keying / Sun, Qian et al. | 2023
- 183
-
COMBINED USE OF MINIMAL RESIDUAL DISEASE MONITORING AND FDG‐PET FOR OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIALFerrero, S. / Assanto, G. M. / Durmo, R. / Marcheselli, L. / Mantoan, B. / Pironti, M. / Guerra, L. / Boccomini, C. / Puccini, B. / Pulsoni, A. et al. | 2023
- 185
-
GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDYPatel, K. / Brown, J. R. / Desikan, S. P. / Nguyen, B. / Won, H. / Tantawy, S. I. / McNeely, S. C. / Marella, N. / Ebata, K. / Woyach, J. A. et al. | 2023
- 187
-
SINGLE‐CELL RNA‐SEQ OF CLASSIC HAIRY CELL LEUKEMIA REVEALS DISEASE DRIVERS LINKED TO INTRINSIC TREATMENT RESISTANCE AND IDENTIFIES DUSP1 AS POTENTIAL NEW THERAPEUTIC TARGETBohn, J. / Salcher, S. / Sturm, G. / Kugler, V. / Feichtner, A. / Fritz, A. / Torres‐Quesada, O. / Mair, A. / Scheiber, A. / Jäger, U. et al. | 2023
- 188
-
IL16 PRODUCTION IS A MECHANISM OF RESISTANCE TO BTK INHIBITORS AND TO R‐CHOPArribas, A. / Napoli, S. / Cascione, L. / Sartori, G. / Cannas, E. / Tarantelli, C. / Spriano, F. / Gaudio, E. / Zucchetto, A. / Rossi, F. M. et al. | 2023
- 189
-
HARNESSING BTKI THERAPY BY CDK4/6I CONTROL OF T CELL SURVEILLANCEChen‐Kiang, S. / Di Liberto, M. / Huang, X. / Inghirami, G. / Martin, P. / Elemento, O. et al. | 2023
- 189
-
ENHANCER RNAS (ERNAS) PLAY A ROLE IN THE RESPONSE TO SMALL MOLECULES AND IN THE DEVELOPMENT OF ACQUIRED RESISTANCE IN MARGINAL ZONE LYMPHOMA (MZL)Napoli, S. / Cascione, L. / Ramnarayanan, S. / Guidetti, F. / Arribas, A. / Rinaldi, A. / Johnson, R. / Bertoni, F. et al. | 2023
- 190
-
IMMUNE‐DEPLETED TUMOR MICROENVIRONMENT IS ASSOCIATED WITH POOR OUTCOMES AND BTK INHIBITOR RESISTANCE IN MANTLE CELL LYMPHOMAJain, P. / Nomie, K. / Kotlov, N. / Hill, H. / Ok, C. Y. / Fetooh, A. / Kanagal‐Shamanna, R. / Vega, F. / Fowler, N. / Wang, M. et al. | 2023
- 192
-
LACK OF SMARCB1 EXPRESSION CHARACTERIZES A SUBSET OF PERIPHERAL T‐CELL LYMPHOMAS ENRICHED IN CHILDREN AND YOUNG ADULTSFischer, A. / Moreno, N. / Interlandi, M. / Albert, T. K. / Mormann, J. / Glaser, S. / Patil, P. / Balbach, S. / Wagener, R. / Bens, S. et al. | 2023
- 192
-
CHROMATIN ACCESSIBILITY PROFILING TO INCREASE DIAGNOSTIC ACCURACY AND REFINE CELL‐OF‐ORIGIN CLASSIFICATION OF MATURE T‐CELL LYMPHOMASJulia, E. / Mareschal, S. / Chebel, A. / Camille, G. / Missaglia, E. / Rattina, V. / Lours, C. / Testard, Q. / Tschantz, M. / Sebai, S. et al. | 2023
- 192
-
Diffuse large B‐cell lymphoma of the Waldeyer's ring: A U.S. population‐based survival analysisFlorindez, Jorge A. / Lossos, Izidore S. / Alderuccio, Juan Pablo et al. | 2023
- 193
-
BRCA1/2 MUTATIONS IMPACT ON THE DEVELOPMENT OF BREAST IMPLANT‐ASSOCIATED LYMPHOMA (BIA‐ALCL) IN WOMEN WITH BREAST CANCER RECONSTRUCTED WITH TEXTURED BREAST IMPLANTSGhione, P. / Arcila, M. / Joseph, V. / Dogan, A. / Cordeiro, P. / Salles, G. / de Jong, D. / Horwitz, S. / Mandelker, D. / van Leeuwen, F. et al. | 2023
- 194
-
A PHASE 2 TRIAL OF CHOP WITH ANTI‐CCR4 ANTIBODY MOGAMULIZUMAB FOR ELDERLY PATIENTS WITH CCR4‐POSITIVE ADULT T‐CELL LEUKEMIA/LYMPHOMAUtsunomiya, A. / Kusumoto, S. / Choi, I. / Yoshimitsu, M. / Shimokawa, M. / Suehiro, Y. / Hidaka, T. / Nosaka, K. / Sasaki, H. / Rai, S. et al. | 2023
- 195
-
AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDYKim, W. S. / Shortt, J. / Zinzani, P. L. / Mikhaylova, N. / Marin‐Niebla, A. / Radeski, D. / Ribrag, V. / Domenech, E. Domingo / Sawas, A. / Alexis, K. et al. | 2023
- 196
-
LACUTAMAB IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES (MF): EFFICACY RESULTS ACCORDING TO UPDATED LYMPH NODE (LN) CLASSIFICATION IN THE TELLOMAK STUDYKim, Y. H. / Bagot, M. / Ortiz‐Romero, P. L. / Zinzani, P. L. / Beylot‐Barry, M. / Dalle, S. / Jacobsen, E. / Combalia, A. / Huen, A. / Mehta‐Shah, N. et al. | 2023
- 196
-
Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classificationKriachok, Iryna / Stepanishyna, Yana / Skrypets, Tetiana / Shokun, Nazar / Martynchyk, Arina / Tytorenko, Iryna / Aleksik, Olena / Krotevych, Mykhailo / Manni, Martina / Federico, Massimo et al. | 2023
- 197
-
PROTEOMIC PROFILING IDENTIFIES GRANZYME B INHIBITOR SERPIN B9 AS MEDIATOR OF RESISTANCE TO CAR T‐CELL AND BISPECIFIC ANTIBODY TREATMENT IN NODAL B‐CELL LYMPHOMABrinkmann, B. J. / Roider, T. / Capraz, T. / Knoll, M. / Kolb, C. / Liu, Y. / Müller‐Tidow, C. / Chapuy, B. / Sauer, T. / Schmitt, M. et al. | 2023
- 198
-
CART‐SIE REAL LIFE STUDY: PRIMARY MEDIASTINAL B‐CELL LYMPHOMA (PMBCL) HAVE A SUPERIOR OUTCOME COMPARED TO LARGE B‐CELL LYMPHOMA (LBCL) TREATED WITH AXICABTAGENE CILOLEUCELChiappella, A. / Dodero, A. / Guidetti, A. / Ljevar, S. / Pennisi, M. / Casadei, B. / Galli, E. / Di Rocco, A. / Cutini, I. / Barbui, A. M. et al. | 2023
- 199
-
IMPACT OF RESPONSE TO SYSTEMIC BRIDGING THERAPY ON CLINICAL OUTCOMES AND CYTOKINE PROFILE IN PATIENTS RECEIVING CAR T‐CELL THERAPY FOR AGGRESSIVE B‐CELL LYMPHOMAWills, B. / Shouval, R. / Flynn, J. / Devlin, S. M. / Shah, G. L. / Scordo, M. / P. B. Dahi / Lin, R. J. / Imber, B. / Parascondola, A. et al. | 2023
- 201
-
BENDAMUSTINE LYMPHODEPLETION TRIGGERS REDUCED INFLAMMATORY CYTOKINES AND DECREASED TOXICITIES AFTER BOTH 4‐1BB‐ AND CD28‐COSTIMULATED CART19 FOR NON‐HODGKIN LYMPHOMAGhilardi, G. / Paruzzo, L. / Svoboda, J. / Chong, E. A. / Cohen, I. J. / Nasta, S. D. / Landsburg, D. J. / Gerson, J. N. / Carter, J. S. / Barta, S. K. et al. | 2023
- 201
-
Role of chemotherapy in the treatment of chronic lymphocytic leukemia in the era of targeted therapies in Italy. A Campus CLL network reportBallotta, Laura / Maccaferri, Monica / De Paoli, Lorenzo / Orsucci, Lorella / Gottardi, Daniela / Chiurazzi, Federico / Reda, Gianluigi / Moia, Riccardo / Cuneo, Antonio / Foà, Robin et al. | 2023
- 202
-
PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER AUTOLOGOUS ANTI‐CD19 CAR T CELLS IN LARGE B‐CELL LYMPHOMA: A DESCAR‐T REGISTRY STUDY FORM THE LYSASesques, P. / Di blasi, R. / Legouill, S. / Cartron, G. / Beauvais, D. / Le Bras, F. / Gros, F. / Choquet, S. / Bories, P. / Rubio, M. et al. | 2023
- 204
-
SEVERE HEMATOLOGICAL TOXICITY FOLLOWING CD19 CAR‐T FOR RELAPSED/REFRACTORY LBCL IS ASSOCIATED WITH SUPPRESSIVE IMMUNE DYSREGULATION AND LIMITED CAR‐T EXPANSIONRejeski, K. / Perez, A. / Iacoboni, G. / Blumenberg, V. / Bücklein, V. L. / Völkl, S. / Penack, O. / Albanyan, O. / Petrera, A. / Reid, K. et al. | 2023
- 205
-
High mortality in fully vaccinated hematologic patients treated with anti‐CD20 antibodies during the “Omicron wave” of COVID‐19 pandemicCattaneo, Chiara / Masina, Lorenzo / Pagani, Chiara / Cancelli, Valeria / Daffini, Rosa / Tucci, Alessandra / Rossi, Giuseppe et al. | 2023
- 205
-
MYC/BCL6 DOUBLE HIT LYMPHOMA NEGATIVE FOR T(3;8) BCL6::MYC FUSION IS ASSOCIATED WITH INFERIOR SURVIVAL, IN CONTRAST WITH T(3;8) POSITIVE PSEUDO‐DOUBLE HIT LYMPHOMAMaybury, B. D. / James, L. / Chadderton, N. / Dowds, J. / Venkatadasari, I. / Riley, J. / Qureshi, I. / Talbot, G. / Giles, H. V. / Phillips, N. J. et al. | 2023
- 207
-
HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R‐CHOP IN PREVIOUSLY UNTREATED (1L) HIGH‐RISK DLBCL, INCLUDING DOUBLE‐HIT/TRIPLE‐HIT: EPCORE NHL‐2 UPDATEFalchi, L. / Clausen, M. R. / Offner, F. / de Vos, S. / Brody, J. / Linton, K. M. / Snauwaert, S. / Cordoba, R. / Wu, J. / Bykhovski, I. et al. | 2023
- 208
-
WAVELINE‐004: OPEN‐LABEL, PHASE 2 STUDY OF ZILOVERTAMAB VEDOTIN (MK‐2140) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)Fosså, A. / Ozcan, M. / Song, Y. / Lee, S. T. / Mensah, F. / Modi, D. / Kim, W. S. / Paszkiewicz‐Kozik, E. / Sawalha, Y. / Sevindik, O. G. et al. | 2023
- 208
-
Convalescent plasma in oncohematological patientsFocosi, Daniele / Franchini, Massimo / Joyner, Michael J. / Henderson, Jeffrey P. / Casadevall, Arturo et al. | 2023
- 209
-
LONG‐TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS‐2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMACaimi, P. F / Ai, W. Z / Alderuccio, J. P. / Ardeshna, K. M / Hamadani, M. / Hess, B. / Kahl, B. S / Radford, J. / Solh, M. / Stathis, A. et al. | 2023
- 210
-
Response to SARS‐CoV‐2 vaccination and antibodies persistence in multiple myeloma patientsPettine, Loredana / Bortolotti, Marta / Fattizzo, Bruno / Da Vià, Matteo C. / Consonni, Dario / Pompa, Alessandra / Bolli, Niccolò / Baldini, Luca et al. | 2023
- 212
-
LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSENastoupil, L. J. / Kamdar, M. / Chavez, J. C. / Ghesquieres, H. / Ghosh, M. / Holmes, H. / López‐Guillermo, A. / Martínez‐López, J. / Novak, U. / Ribrag, V. et al. | 2023
- 213
-
Reply to “successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients—A Czech multicenter experience”: A case series of SARS‐CoV‐2 Omicron infection and aggressive lymphoma in the Sotrovimab eraCassin, Ramona / Rampi, Nicolo / C, Fidanza / Muscatello, Antonio / Mariani, Bianca / Noto, Alessandro / Rossi, Francesca Gaia / Baldini, Luca et al. | 2023
- 214
-
COMPARATIVE ACCURACY OF ALTERNATIVE EARLY MEASURES OF RESIDUAL DISEASE AFTER CAR19 THERAPY OF RELAPSED/REFRACTORY LBCLSworder, B. J. / Alig, S. K. / Shukla, N. / Garofalo, A. / Macaulay, C. W. / Esfahani, M. Shahrokh / Olsen, M. N. / Hamilton, J. / Hosoya, H. / Hamilton, M. P. et al. | 2023
- 216
-
RITUXIMAB‐CONTAINING COMBINED MODALITY THERAPY IN LIMITED STAGE FOLLICULAR LYMPHOMA: MATURE FOLLOW UP AND DERIVATION OF A NOVEL PROGNOSTIC SCORE FROM THE TROG99.03 TRIALTobin, J. W. / Jurinovic, V. / Tsang, H. / Roos, D. / Tsang, R. / Macann, A. / Davis, S. / Christie, D. / Law, S. / Nath, K. et al. | 2023
- 217
-
RADIOTHERAPY BRIDGING IN LARGE B‐CELL LYMPHOMA PATIENTS RECEIVING CD19 CAR‐T – THE UK EXPERIENCEKuhnl, A. / Roddie, C. / Kirkwood, A. / Chaganti, S. / Norman, J. / Lugthart, S. / Osborne, W. / Gibb, A. / Arias, C. Gonzalez / Latif, A. et al. | 2023
- 218
-
HIGH RATE OF METABOLIC COMPLETE RESPONSE AFTER LOW DOSE RADIOTHERAPY AND OBINUTUZUMAB IN EARLY STAGE FOLLICULAR LYMPHOMA: INITIAL RESULTS OF THE GAZAI STUDY (GLA 2018‐3)Herfarth, K. / Scholz, C. W. / Hübel, K. / Wirths, S. / Buske, C. / Dürig, J. / Forstpointner, R. / Heidegger, S. / Lenz, G. / König, L. et al. | 2023
- 220
-
VERY LOW DOSE RADIATION THERAPY FOR INDOLENT LYMPHOMA: COMPARING “BIG BOOM” (4GY × 1) VERSUS “BOOM BOOM” (2GY × 2)Hajj, C. / Lee, J. / Boe, L. / Fregonese, B. / Lebow, E. / Wijetunga, N. A. / Hubbeling, H. / Tringale, K. / Freret, M. / Imber, B. et al. | 2023
- 221
-
SALVAGE RADIOTHERAPY IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA AFTER CAR T‐CELL THERAPY FAILUREAbabneh, H. S. / Ng, A. K. / Frigault, M. J. / Abramson, J. S. / Johnson, P. C. / Jacobson, C. A. / Patel, C. G. et al. | 2023
- 221
-
Review on natural killer/T‐cell lymphomaHe, Xiaohua / Gao, Yan / Li, Zhiming / Huang, Huiqiang et al. | 2023
- 222
-
BONE MARROW VOLUME IRRADIATED AND RISK OF CYTOPENIAS IN AGGRESSIVE B‐CELL LYMPHOMA PATIENTS BRIDGED WITH RADIATION THERAPY FOR CART CELL THERAPYManzar, G. S. / Dabaja, B. S. / Wu, S. Y. / Nasr, L. F. / Dudzinski, S. O. / Yoder, A. K. / Corrigan, K. L. / Gunther, J. R. / Ahmed, S. / Spiotto, M. et al. | 2023
- 223
-
IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCYMorschhauser, F. / Hatzi, K. / Lenz, G. / Herrera, A. F. / Flowers, C. R. / Trněný, M. / Burke, J. M. / Hou, J. / Staber, P. B. / Hawkes, E. A. et al. | 2023
- 225
-
SPATIALLY‐RESOLVED TRANSCRIPTOMICS DEFINE CLINICALLY RELEVANT SUBSETS OF MACROPHAGES IN DIFFUSE LARGE B‐CELL LYMPHOMALiu, M. / Bertolazzi, G. / Mulder, K. / Sridhar, S. / Tripodo, C. / Jeyasekharan, A. D. et al. | 2023
- 226
-
COORDINATED CHANGES IN THE TUMOR MICROENVIRONMENT (TME) ARE ASSOCIATED WITH INCREASED RISK OF THERAPEUTIC FAILURE IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)Soekojo, C. Y. / Whitaker, K. R. / Ferre, R. Leon / Moore, R. M. / Maurer, M. J. / Villasboas, J. C. et al. | 2023
- 228
-
EZH2 INHIBITION ENHANCES CAR T ANTITUMOR EFFECT BY INDUCING LYMPHOMA IMMUNOGENICITY AND ENHANCING T CELL FUNCTIONIsshiki, Y. / Porazzi, P. / Melnick, A. / Ruella, M. / Béguelin, W. et al. | 2023
- 228
-
SINGLE CELL ANALYSIS REVEALS IMMUNE DYSFUNCTION IN LARGE B CELL LYMPHOMA (LBCL) PTS WITH HYPOMAGNESEMIA RECEIVING AXI‐CEL: RESULTS FROM ZUMA‐1 TRIAL AND MAYO CLINIC COHORTMondello, P. / Gile, J. / Wang, Z. / Li, Y. / Bansal, R. / Gandhi, S. / Zhang, H. / Babadi, E. / Martinez, K. / McCoy, G. et al. | 2023
- 230
-
FOLLICULAR LYMPHOMA PATIENT‐DERIVED ORGANOIDS FOR BISPECIFIC T‐CELL ENGAGER IMMUNOTHERAPYSchroers‐Martin, J. G. / Kastenschmidt, J. / Sworder, B. J. / Diehn, M. / Wagar, L. / Alizadeh, A. A. et al. | 2023
- 230
-
Elevated serum IL‐13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B‐cell lymphomaLi, Xiao / Liu, Mengke / Shi, Qing / Fang, Ying / Fu, Di / Shen, Zhi‐xiang / Yi, Hongmei / Wang, Li / Zhao, Weili et al. | 2023
- 231
-
5‐YEAR (Y) FOLLOW‐UP OF A PHASE 2 STUDY OF IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER CLL PATIENTS (PTS)Ahn, I. E. / Brander, D. M. / Ren, Y. / Zhou, Y. / Tyekucheva, S. / Walker, H. A. / Black, R. / Montegaard, J. / Alencar, A. / Shune, L. et al. | 2023
- 233
-
LONG‐TERM FOLLOW‐UP OF MULTICENTER PHASE II TRIAL OF ZANUBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX (BOVEN) IN PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLLSoumerai, J. D. / Dogan, A. / Seshan, V. / Flaherty, K. / Carter, J. / Hochberg, E. / Barnes, J. A. / Abramson, J. S. / Hamilton, A. M. / Noy, A. et al. | 2023
- 235
-
ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDYShadman, M. / Munir, T. / Roback, T. / Brown, J. R. / Kahl, B. S. / Ghia, P. / Giannopoulos, K. / Šimkovič, M. / Österborg, A. / Laurenti, L. et al. | 2023
- 238
-
FIXED‐DURATION IBRUTINIB + VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM THE FD COHORT OF THE PHASE 2 CAPTIVATE STUDYGhia, P. / Allan, J. N. / Siddiqi, T. / Wierda, W. G. / Tam, C. S. / Moreno, C. / Tedeschi, A. / Szafer‐Glusman, E. / Zhou, C. / Abbazio, C. et al. | 2023
- 239
-
MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)Kater, A. P. / Harrup, R. / Kipps, T. J. / Eichhorst, B. / Owen, C. J. / Assouline, S. / Lamanna, N. / Robak, T. / Serna, J. d. l. / Jaeger, U. et al. | 2023
- 239
-
Improved method to stratify lymphoma patients with risk of secondary central nervous system involvement: A multicenter retrospective analysisLang, Mingxiao / Feng, Youqin / Meng, Xiangrui / Zhao, Jing / Song, Zheng / Qian, Zhengzi / Qiu, Lihua / Zhou, Shiyong / Liu, Xianming / Li, Lanfang et al. | 2023
- 243
-
Impact of the Affordable Care Act and Medicaid Expansion on Insurance Coverage and Outcomes in Patients with HIV‐associated Aggressive B‐cell Non‐Hodgkin LymphomasPremnath, N. / Reves, H. / Pandey, U. / Anderson, J. / Afrough, A. / Anderson, L. D. / Madanat, Y. F. / Collins, R. H. Jr / Chung, S. / Kaur, G. et al. | 2023
- 244
-
TESTICULAR LARGE B‐CELL LYMPHOMA IS GENETICALLY SIMILAR TO PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA AND DISTINCT FROM NODAL DIFFUSE LARGE B‐CELL LYMPHOMARivas‐Delgado, A. / López, C. / Clot, G. / Nadeu, F. / Grau, M. / Frigola, G. / Bosch, J. / Radke, J. / Ishaque, N. / Alcoceba, M. et al. | 2023
- 246
-
Subgrouping of Burkitt lymphoma variants by DNA methylation is driven by an EBV‐associated epigenotypeGlaser, S. / Del Val, C. / Wagener, R. / Kretzmer, H. / Klapper, W. / Hummel, M. / Ammerpohl, O. / Lichter, P. / Burkhardt, B. / Trümper, L. et al. | 2023
- 247
-
A transposable element atlas of aggressive B‐cell non‐Hodgkin lymphomas defines novel classifications of Burkitt lymphoma independent of EBV statusSingh, B. / Dopkins, N. / Fei, T. / Michael, S. / Marston, J. L. / Hernandez, M. M. A. / Heymann, J. J. / Chadburn, A. / Martin, P. / Leal, F. et al. | 2023
- 248
-
Genomic characterization of lymphomas in patients with inborn errors of immunityPan‐Hammarström, Q. et al. | 2023
- 248
-
Primary treatment and recent survival trends in patients with primary diffuse large B‐cell lymphoma of central nervous system, 1995–2016: A population‐based SEER analysisChen, Cui / Sun, Peng / Sun, Xiao‐Qing / Chen, Shao‐Yong / Hang Yang / Wang, Yu / Li, Zhi‐Ming et al. | 2023
- 248
-
Characterization of the genetic and epigenetic landscape of B‐cell neoplasms with IG::BCL3‐translocationDrewes, C. / López, C. / Okeke, N. / Hillebrecht, S. / Schütz, P. / Fischer, A. / Mottok, A. / Bens, S. / Schneider, C. / Stilgenbauer, S. et al. | 2023
- 249
-
Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia (CLL) From a Head‐to‐Head Trial of Acalabrutinib Versus IbrutinibWoyach, J. A. / Jones, D. / Jurczak, W. / Robak, T. / Illés, A. / Kater, A. P. / Ghia, P. / Byrd, J. C. / Seymour, J. F. / Long, S. et al. | 2023
- 250
-
The RNA helicase DDX21 cooperates with ETS1 and FLI1 in cell cycle regulation and small nucleolar RNA processing to sustain the survival of DLBCL cellsSartori, G. / Priebe, V. / Cascione, L. / Favre‐Juilland, M. / Chung, E. Y. / Napoli, S. / Arribas, A. / Rinaldi, A. / Miazza, M. Thome / Bertoni, F. et al. | 2023
- 251
-
Alpha‐ketoglutarate Suppresses Tumor Growth of Diffuse Large B‐cell Lymphoma by Inducing FerroptosisCai, Y. / Lv, L. / Lu, T. / Ding, M. / Zhan, L. / Zhou, X. / Wang, X. et al. | 2023
- 253
-
CTPS1 acts as a prognostic biomarker and therapeutic target in mantle cell lymphomaLiang, J. / Ren, Y. / Du, K. / Wang, L. / Wang, R. / Li, J. / Xu, W. et al. | 2023
- 254
-
Lipid metabolism reprogramming roles in mantel cell lymphoma growth and survivalLiang, J. / Guo, J. / Du, K. / Shen, H. / Yin, H. / Wu, J. / Wang, L. / Li, J. / Xu, W. et al. | 2023
- 255
-
Deciphering the role of MSI2 as a regulator of stem‐like properties in mantle cell lymphomaAmador, V. / Sureda‐Gómez1, M. / Balsas, P. / Rodríguez, M. / De Bolòs, A. et al. | 2023
- 256
-
Lymph node location and retention properties of DC‐SIGN engagement with the Immunoglobulin Oligomannoses of Follicular LymphomaChiodin, G. / Tatterton, D. / Zhang, Y. / Duriez, P. / Ertay, A. / Rock, P. / del Rio, L. / Sale, B. / Lanham, S. / Stevenson, F. et al. | 2023
- 256
-
CD30 protects EBV‐positive diffuse large B‐cell lymphoma cells against mitochondrial dysfunction through increasing BNIP3 expressionLiang, J. / Wang, W. / Xing, T. / Guo, J. / Li, J. / Xu, W. et al. | 2023
- 257
-
Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphomaSong, Wenting / Chen, Zhan / Shi, Cunzhen / Gao, Yuyang / Feng, Xiaoyan / Li, Hongwen / Li, Zhaoming / Zhang, Mingzhi et al. | 2023
- 258
-
Unraveling the mechanisms of c‐MYC‐mediated escape from antibody and T‐cell based anti‐tumor immune attack in B‐cell malignanciesde Jonge, V. / Csikós, T. / Eken, M. / Roemer, M. / Chamuleau, M. / Mutis, T. et al. | 2023
- 258
-
Activation of the Novel Tumor Suppressor SAMHD1 Inhibits Cell Growth and Induces Interferon‐beta (IFN‐β) Gene Expression in Classical Hodgkin Lymphoma (cHL)Xagoraris, I. / Stathopoulou, K. / Binh Nordentoft, C. An / Xyderou, P. / Kurzay, A. / Lundqvist, A. / Herold, N. / Rassidakis, G. et al. | 2023
- 260
-
Deciphering the role of macrophages and T cells in primary central nervous system lymphoma: tumour aggressiveness and response to immunotherapiesPagès‐Geli, C. / Medina‐Gil, D. / Fernández‐Guzmán, P. / Hernández, C. / Crespo, M. et al. | 2023
- 261
-
The Immunobiology of histologic transformation in follicular lymphoma: a multi‐omic case‐control studySoekojo, C. Y. / Whitaker, K. R. / Ferre, R. Leon / Maurer, M. / Villasboas, J. C. et al. | 2023
- 262
-
Spatial transcriptomic profiling: The “Next Generation Diagnosis” distinguishing between EBV+ lymphoproliferations with Hodgkin‐like featuresPugh, M. R. / Fennell, E. / Leopold, G. / Murray, P. G. / Dojcinov, S. D. et al. | 2023
- 263
-
Combined single‐cell and spatially‐resolved mapping of lymph node ecosystems reveals principles of lymphoma tissue organizationCzernilofsky, F. / Mathioudaki, A. / Jopp‐Saile, L. / Lutz, R. / Vonficht, D. / Baertsch, M. / Vohringer, H. / Roider, T. / Ordoñez‐Rueda, D. / Pabst, C. et al. | 2023
- 264
-
Digital spatial profiling of the tumor microenvironment in Hodgkin‐like adult T‐cell leukemia/lymphomaTakeuchi, M. / Miyoshi, H. / Yamada, K. / Nakashima, K. / Sato, K. / Furuta, T. / Moritsubo, M. / Imamoto, T. / Arakawa, F. / Kouno, K. et al. | 2023
- 265
-
Single‐cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi‐Resistant proliferative drive CLL patientsSha, Y. / Qin, S. / Miao, Y. / Xia, Y. / Lu, X. / Dai, L. / Qiu, T. / Wu, W. / Fan, L. / Xu, W. et al. | 2023
- 266
-
Characterization of the tumor microenvironment in classic Hodgkin lymphoma: determining the deep immunophenotypic signature of T cells using mass cytometryNiu, A. / Whitaker, K. / Soekojo, C. Y. / Yang, Z. Z. / Kim, H. J. / Novak, A. J. / Ansell, S. M. / Villasboas, J. C. et al. | 2023
- 267
-
Prognostic values of circulating TREM2+ and ARG1+ Mreg cells in adults with treatment‐naïve diffuse large B‐cell lymphomaWang, H. / Yang, F. / Yang, C. / Ko, P. / Li, C. / Liu, Y. / Tsai, C. / Liu, J. / Chen, P. / Chen, N. et al. | 2023
- 267
-
Clinical analysis of patients with primary and secondary extranodal natural killer/T‐cell lymphoma of central nervous systemLi, Xingying / Yu, Hui / Fu, Xiaorui / Zhang, Lei / Li, Xin / Li, Ling / Wang, Xinhua / Sun, Zhenchang / Zhang, Xudong / Li, Zhaoming et al. | 2023
- 269
-
Pembrolizumab in combination with epigenetic therapy is safe and active in heavily treated patients with peripheral T‐cell lymphoma and cutaneous T‐cell lymphomaRoberts, N. L. / Lister, J. / Benani, N. N. / Jain, S. / Battaglia, T. / Abdelmalek, M. / Ayers, E. C. / Portell, C. / Williams, M. E. / Batchala, P. et al. | 2023
- 270
-
Genomic abnormalities involving class I HLA are common in advanced cutaneous T‐cell lymphomaKwang, A. C / Duran, G. E. / Li, S. / Torres, A. N. Bastidas / Herrera, M. / Wang, E. B. / Kurtz, D. M. / Kim, Y. H. / Khodadoust, M. S. et al. | 2023
- 272
-
T cell CD62L expression following nivolumab therapy is associated with response to rituximab‐nivolumab in treatment naïve follicular lymphoma: the 1st FLOR studyKoldej, R. M. / Barraclough, A. / Lee, S. T. / Morgan, H. / Holzwart, N. / Koshy, M. / Smith, C. / Chong, G. / Gilbertson, M. / Keane, C. et al. | 2023
- 272
-
RHOA deficiency drives decreased CD19 expression and immune dysregulation in CAR‐T resistant diffuse large B‐cell lymphomaNewsam, A. / Coughlin, C. / Goretsky, Y. / Sondhi, A. / Roberts, E. / Bilbao, D. / Ziccheddu, B. / Manera, P. / Maura, F. / Schatz, J. et al. | 2023
- 273
-
Shelter in place: Live CLL cells inside the bone marrow fibroblasts and its implication in drug resistanceWang, Y. L. / Vistarop, A. / Franzen, C. / Efimov, A. / Patel, P. / Lu, P. / Ma, S. / Cukierman, E. / Franco‐Barraza, J. / Gao, J. et al. | 2023
- 274
-
Degradation of CD47‐SIRPα axis by pomalidomide potentiates CD20 antibody‐dependent cellular phagocytosis against B‐cell lymphomaGuo, H. / Wang, H. / Yang, J. / Liu, Y. / Liu, X. / Zhang, Q. / Zhou, K. et al. | 2023
- 275
-
Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti‐CD19‐chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B‐cell lymphoma and high tumor burdenMu, Juan / Deng, Haobin / Lyu, Cuicui / Yuan, Jijun / Li, Qing / Wang, Jia / Jiang, Yanyu / Deng, Qi / Shen, Jichun et al. | 2023
- 275
-
SAR442257, a CD38/CD28/CD3 trispecific antibody, potentiates CAR T‐cell activity against large B‐cell lymphomaGreen, M. R. / Reville, P. K. / Dai, E. / Sheikh, I. / Deng, Q. / Henderson, J. / Le, C. / Rojas, E. / Okwuchi, C. / Wilson, A. et al. | 2023
- 275
-
Targeting monocytic‐myeloid suppressor cells through CSF1R‐blockade enhances CD19‐CAR T‐cell response in DLBCLGödel, P. / Stahl, D. / Riet, T. / Flümann, R. / Chmielewski, M. / Blakemore, S. / Segbers, P. / Tetenborg, L. / Reinhardt, H. C. / Borchmann, P. et al. | 2023
- 276
-
Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphomaTobin, J. W. / Tsang, H. / Patch, A. / Keane, C. / Law, S. C. / Gunawardana, J. / Blombery, P. / Thompson, E. R. / Sabdia, M. B. / De Long, L. M. et al. | 2023
- 277
-
Metabolic reprograming of exhausted intratumoral CD8+ T‐cell underlies anti‐tumor activity of SUMOylation inhibitors in Large B Cell LymphomaLownik, J. / Milshteyn, L. / Villamejor, A. L. / Merchant, A. A. et al. | 2023
- 278
-
Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapseSwain, F. / Burgess, M. / Kempe, S. / Sabdia, M. / Wight, J. / Hawkes, E. / Mutsando, H. / Talaulikar, D. / Merida de Long, L. / Hawula, Z. et al. | 2023
- 280
-
Itk inhibitor induces Th1 skewing and host anti‐tumor response mediated by CD8+ TEMRA cells in refractory T cell lymphoma patientsDing, N. / Xie, Y. / Miller, R. / Mahabhashyam, S. / Hsu, L. / Guo, Y. / Li, K. C. / Du, T. / Mi, L. / Lin, N. et al. | 2023
- 280
-
Enhancing T‐cell responses to GCB‐like lymphomas with immune‐checkpoint‐blockade‐based therapiesSerganova, I. / Bucktrout, R. / Isshiki, Y. / Sarapulov, A. / Santella, A. / Rodriguez, M. / Chakraborty, S. / Brunschvig, S. / Qualls, D. / Vardhana, S. et al. | 2023
- 281
-
Determinants of response to T‐cell stimulation by CD27 antibody therapy in lymphoma: The RiVa trialRose‐Zerilli, M. J. / Buermann, L. / Stanton, L. / Wignall, C. M. / Coleman, A. R. / Thorne, K. / Keyworth, N. / Konn, Z. / Turaj, A. H. / McKay, P. et al. | 2023
- 283
-
Gut microbiome in DLBCL patients undergoing first‐line R‐CHOP regimen—The Oncopassport StudyStefoni, V. / Argnani, L. / Casadei, B. / Musuraca, G. / Nanni, L. / Pellegrini, C. / Broccoli, A. / Carella, M. / Caldarulo, E. / Mammoli, F. et al. | 2023
- 285
-
TAFRO syndrome with fatigue and abdominal distension as the first symptom: A case reportZhou, Bai / Tang, Chao / Chen, Guiyang / Jiang, Tiebin / Shi, Xiao / Wang, Fen et al. | 2023
- 285
-
Microbiota diversity in patients with Diffuse Large B‐Cell Lymphoma and Immune‐Privileged Sites LymphomaDlouha, L. / Tenglerova, M. / Rehakova, J. / Brichova, M. / Kostovcik, M. / Benesova, K. / Kverka, M. / Heissigerova, J. / Svozilkova, P. / Ondeckova, I. et al. | 2023
- 286
-
TAyloring LYmphoma therapy with Immune Escape Signatures from 3D avatars of B‐cell NHLGava, F. / Faria, C. / Gravelle, P. / Garcia‐Valero, J. / Quelen, C. / Serrat, N. / Gower, N. / Morschhauser, F. / Fournié, J. / Bouquet, F. et al. | 2023
- 287
-
Study of the efficacy of novel bispecific antibodies targeting immune checkpoints in a 3D model of B non‐Hodgkin lymphomaGower, N. / Gava, F. / Rimailho, L. / Faria, C. / Gravelle, P. / Perez‐Galan, P. / Serrat, N. / Bouquet, F. / Fonseca, C. / Herter, S. et al. | 2023
- 288
-
Identification of an activated/memory B‐cell signature of poor outcome and sensitivity to lenalidomide in follicular lymphoma patientsLaurent, C. / Trisal, P. / Tesson, B. / Lesne, B. / Van‐Acker, N. / Chartier, L. / Stokes, M. / Huang, C. / Huet, S. / Morschhauser, F. et al. | 2023
- 290
-
A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trialMozas, P. / Ammar, R. Ould / Chartier, L. / Nastoupil, L. / Bachy, E. / Bezsera, S. M. / Barnes, J. / Bijou, F. / Goy, A. / Zerazhi, H. et al. | 2023
- 291
-
Genetic Alterations in Follicular Lymphoma Predict Response to Very Low Dose RadiotherapyWijetunga, N. A. / Lebow, E. / Chan, A. / Lee, J. / Fregonese, B. / Hajj, C. / Cedarquist, G. / Hubbeling, H. / Ma, J. / Sarkar, R. et al. | 2023
- 292
-
Proteomic profiling identifies apoptotic deregulation predictive of histological transformation in follicular lymphomaEnemark, M. B. H. / Sørensen, E. F. / Andersen, M. D. / Campbell, A. J. / Hybel, T. E. / Madsen, C. / Lauridsen, K. L. / F. d'Amore / Plesner, T. L. / Hamilton‐Dutoit, S. J. et al. | 2023
- 293
-
Richter transformation in Chronic Lymphocytic LeukemiaInnocenti, Idanna / Benintende, Giulia / Tomasso, Annamaria / Fresa, Alberto / Autore, Francesco / Larocca, Luigi Maria / Laurenti, Luca et al. | 2023
- 294
-
Assessment of Helicobacter pylori (HP) negative gastric MALT lymphoma for non‐H.pylori Helicobacter using multiplex PCR: a retrospective analysisRaderer, M. / Simonitsch‐Klupp, I. / Staudacher, M. / Hotz, J. / Kritz, R. / Schefberger, K. / Kiesewetter, B. / Lagler, H. et al. | 2023
- 294
-
Impact of the Dark Zone Signature on Central Nervous System Relapse in a Real‐World Diffuse Large B‐cell Lymphoma PopulationAlduaij, W. / Jiang, A. / Collinge, B. / Ben‐Neriah, S. / Hilton, L. K. / Boyle, M. / Meissner, B. / Farinha, P. / Slack, G. / Villa, D. et al. | 2023
- 296
-
Identification of biomarkers for predicting central nervous system involvement in patients with diffuse large B‐cell lymphomaPagès‐Geli, C. / Bobillo, S. / Abrisqueta, P. / Castellví, J. / Palomo, L. / Alvarez‐Errico, D. / Esteller, M. / Bosch, F. / Crespo, M. et al. | 2023
- 297
-
Predicting cell of origin from digitized images of hematoxylin and eosin‐stained slides of diffuse large B‐cell lymphomas using a cell‐based deep‐learning modelYüce, A. / Gildenblat, J. / Abbasi‐Sureshjani, S. / Laurent, C. / Korski, K. et al. | 2023
- 298
-
MYC negatively impacts treatment outcomes in stage II, but not stage I diffuse large B‐cell lymphomade Jonge, V. / Bult, J. / Karssing, D. / Nijland, M. / Chamuleau, M. / Brink, M. et al. | 2023
- 299
-
A sub‐population of cells expressing MYC and BCL2 without BCL6 refines the definition of double expressor lymphoma (DEL)Hoppe, M. M. / Sridhar, S. / Liu, M. / Jaynes, P. / Peng, Y. / Harris, C. III / Bottos, A. / Farinha, P. / Mottok, A. / Scott, D. W. et al. | 2023
- 300
-
Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitorShi, Z. / Fang, Y. / Xu, P. / Yi, H. / Li, J. / Dong, Y. / Zhu, Y. / Liu, M. / Fu, D. / Wang, S. et al. | 2023
- 301
-
Biological and clinical relevance of CD79 protein and gene expression in diffuse large B‐cell lymphomaNaoi, Y. / Chijimatsu, R. / Urata, T. / Sunami, K. / Imai, T. / Nawa, Y. / Hiramatsu, Y. / Yamamoto, K. / Fujii, S. / Yoshida, I. et al. | 2023
- 301
-
Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancyCao, Han‐Yu / Li, Ling / Xue, Sheng‐Li / Dai, Hai‐Ping et al. | 2023
- 302
-
Genetic and transcriptomic analyses of diffuse large B‐cell lymphoma patients with poor outcomes within two years of diagnosisRen, W. / Own, S. A. / Wan, H. / Berglund, M. / Wang, X. / Yang, M. / Li, X. / Liu, D. / Sonnevi, K. / Enblad, G. et al. | 2023
- 304
-
Genomic Correlates of Radiosensitivity in Diffuse Large B Cell LymphomaSarkar, R. R. / Ma, J. / Wijetunga, N. A. / Salles, G. / Joffe, E. / Imber, B. / Yahalom, J. et al. | 2023
- 305
-
Deep learning can predict presence of TP53 aberrations and IGHV mutational status from peripheral blood smears of chronic lymphocytic leukemiaPachong, S. Mebwe / Robrecht, S. / Ligtvoet, R. / Tausch, E. / Schneider, C. / Fürstenau, M. / von Tresckow, J. / Huber, H. / Stilgenbauer, S. / Cramer, P. et al. | 2023
- 306
-
Next Generation Sequencing in routine diagnostics of mature non‐Hodgkin’s lymphomas. A single‐center real‐life data studyBreinholt, M. F. / Schejbel, L. / Gang, A. O. / Nielsen, T. H. / Pedersen, L. M. / Høgdall, E. / Nørgaard, P. et al. | 2023
- 307
-
Machine Learning‐Based Stem Cell‐Like Phenotype Identification and Novel Risk Stratification in Diffuse Large B‐Cell Lymphoma: Multi‐Omics Data from Multicenter StudiesLiang, X. / Liang, Y. / Wang, X. / Jia, Y. / Young, K. H. / Feng, L. / Wang, L. et al. | 2023
- 309
-
LONG‐TERM FOLLOW‐UP AND GENE EXPRESSION PROFILES ASSOCIATED WITH OUTCOME IN PATIENTS WITH RELAPSED AGGRESSIVE B‐ OR T‐CELL LYMPHOMAS TREATED IN THE NORDIC P[R]EBEN TRIALRelander, T. / Leivonen, S. / Larsen, T. S. / Brown, P. / Jørgensen, J. M. / Mannisto, S. / Lugtenburg, P. / Holte, H. / Fagerli, U. M. / Lauritzsen, G. F. et al. | 2023
- 310
-
Interaction between gut microbiome and immune checkpoint inhibitor treatment in lymphoma patients: Final results of the MICRO‐LINF studyCasadei, B. / Argnani, L. / Guadagnuolo, S. / Nanni, L. / Pellegrini, C. / Broccoli, A. / Carella, M. / Stefoni, V. / Conti, G. / Turroni, S. et al. | 2023
- 310
-
TAFRO syndrome: A disease that known is half curedChen, Tingting / Feng, Chun / Zhang, Xinyou / Zhou, Jihao et al. | 2023
- 311
-
Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T‐cell Project 2.0.Manni, M. / Chiattone, C. S. / Prince, M. H. / Pavlovsky, A. / Tomuleasa, C. / Miranda, E. / Kriachok, I. / Hawkes, E. A. / Fiad, L. / Hitz, F. et al. | 2023
- 312
-
Angioimmunoblastic T cell lymphoma prognostic index in Asian population identifies low risk patients with unique gene expression profilesChang, E. W. Y. / Yang, V. S. / Ong, S. Y. / Lim, B. Y. / Mel, S. d. / Ng, E. K. / Poon, M. L. / Tan, Y. H. / Chang, J. / Poon, E. et al. | 2023
- 313
-
Identifying the mechanistic differences between hypomethylating agents for the treatment of peripheral T cell lymphomaPal, I. / Scotto, L. / Sabzevari, A. / Kinahan, C. / Fox, T. E. / Feith, D. J. / Marchi, E. / Loughran, T. P. Jr. / O'Connor, O. A. et al. | 2023
- 314
-
Serum Triglyceride and Apolipoprotein A1 as Biomarkers for Extranodal Natural Killer/T cell Lymphoma (ENKTL): A Multicenter StudyCai, Q. / Zhao, W. / Wang, L. / Li, Z. / Guo, H. / Wang, J. / Xiong, J. / Huang, H. / Xia, Y. / Tian, X. et al. | 2023
- 315
-
Soluble immune checkpoints HVEM and TIM‐3 are prognostic biomarkers for outcome in classical Hodgkin lymphomaFerdinandus, J. / Cirillo, M. / Bröckelmann, P. J. / von Tresckow, B. / Klapper, W. / Engert, A. / Borchmann, P. / Borchmann, S. et al. | 2023
- 316
-
A gene expression signature to predict disease progression for Hodgkin Lymphoma patients who achieve a complete metabolic response after 2 ABVD coursesDonati, B. / Nizzoli, M. E. / Durmo, R. / Ruffini, A. / Versari, A. / Merli, F. / Ciarrocchi, A. / Luminari, S. et al. | 2023
- 317
-
Deregulated hsa‐miR‐23a‐3p and hsa‐mir‐148a‐3p influence key processes in classic Hodgkin lymphoma (cHL) pathogenesisPaczkowska, J. / Janiszewska, J. / Ustaszewski, A. / Bein, J. / Skalski, M. / Schneider, M. / Bednarek, K. / Hansmann, M. / Dzikiewicz‐Krawczyk, A. / Rozwadowska, N. et al. | 2023
- 318
-
STING is Expressed by Hodgkin and Reed Sternberg (HRS) Cells in a Subset of Classical Hodgkin Lymphoma (cHL) and Correlates with Tumor Microenvironment and Immune ResponseXagoraris, I. / Mulder, T. / Stathopoulou, K. / Xyderou, P. / Andersson, M. / Palma, M. / Rassidakis, G. et al. | 2023
- 319
-
Clinical utility of circulating tumor DNA qualification and quantification in classical Hodgkin lymphomaPirosa, M. C. / Bruscaggin, A. / Terzi di Bergamo, L. / Salehi, M. / Spina, V. / Pini, K. / Bocchetta, S. / Giordano, C. / Forestieri, G. / Condoluci, A. et al. | 2023
- 319
-
Proteomic profiling differentiates classic Hodgkin lymphoma with and without skeletal involvement at the time of diagnosisAndersen, M. D. / Enemark, M. B. / Pedersen, M. A. / Gormsen, L. C. / Lauridsen, K. L. / Starklint, J. / Hamilton‐Dutoit, S. J. / Ludvigsen, M. / d'Amore, F. A. / Honoré, B. et al. | 2023
- 321
-
Distinct molecular determinants of treatment‐failure in elderly Hodgkin lymphoma identified by cell‐free DNA profiling: A LYSA StudyRossi, C. / Boegeholz, J. L. / Alig, S. K. / Garofolo, A. / Esfahani, M. Shahrokh / Schroers‐Martin, J. / Olsen, M. / Kang, X. / Kurtz, D. M. / Sugio, T. et al. | 2023
- 322
-
PET interim results could promptly select Follicular Lymphoma patients in need of maintenance therapy. Potential additional value of ctDNAJiménez‐Ubieto, A. / Poza, M. / López‐Pereira, P. / Figaredo, G. / Sarandeses, P. / Martin‐Muñoz, A. / Barrio, S. / Cortés, M. / Íñiguez, R. / Zamanillo, I. et al. | 2023
- 323
-
The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myelomaEseonu, Kelechi C. / Panchmatia, Jaykar R. / Streetly, Matthew J. / Grauer, Jonathan N. / Fakouri, Bahram et al. | 2023
- 323
-
Genetic characterization in tissue and cfDNA in marginal zone lymphomasDiez‐Feijóo, R. / Lafuente, M. / Garcia‐Gisbert, N. / Fernández‐Rodríguez, C. / Pinzón, S. / Sánchez‐González, B. / Gibert, J. / Fernández‐Ibarrondo, L. / Camacho, L. / Longarón, R. et al. | 2023
- 324
-
Serial circulating tumor DNA sequencing reveals clonal dynamics and can offer treatment guidance in relapsed/refractory diffuse large B‐cell lymphomaHeger, J. M. / Mattlener, J. / Schneider, J. / Schütte, D. / Gödel, P. / Becker, K. / Kutsch, N. / Balke‐Want, H. / Schwarz, R. F. / Reinhardt, H. C. et al. | 2023
- 326
-
Evaluation of ctDNA in a phase I/II trial in relapsed or refractory large B‐cell lymphoma of epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T‐cell–engaging antibodySoong, D. / Thieblemont, C. / Karavitis, J. / Hess, B. / Caimi, P. / Feldman, T. / Hutchings, M. / Sureda, A. / Szafer‐Glusman, E. / Sacchi, M. et al. | 2023
- 328
-
Circulating tumour DNA concentration and genetic classification improve risk stratification in newly diagnosed patients with Diffuse Large B‐Cell LymphomaArzuaga‐Mendez, J. / Bilbao, N. / Lopez‐Lopez, E. / Rivas‐Delgado, A. / Enjuanes, A. / López‐Guillermo, A. / Amutio, E. / Martin‐Guerrero, I. / Garcia‐Ruiz, J. C. et al. | 2023
- 329
-
Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi‐cel) in large B‐cell lymphoma (LBCL)Miles, B. R. / Mao, D. / Vardhanabhuti, S. / To, C. / Schupp, M. / Shahani, S. / Xu, H. / Munoz, J. L. / Westin, J. / Shen, R. et al. | 2023
- 330
-
Clinical implications of ctDNA in predicting the genetic subtype, CNS involvement and outcomes of newly diagnosed diffuse large B cell lymphomaLiang, J. / Wu, Y. / Shen, H. / Yin, H. / Wu, J. / Li, Y. / Wang, L. / Li, J. / Xu, W. et al. | 2023
- 332
-
Molecular characterization of diffuse large‐B cell lymphoma by liquid biopsy at diagnosis and during follow‐up. OBO "Euroclonality‐NGS group" & "Grupo Colaborativo Linfomas y SLP de CyL"Alcoceba, M. / Stewart, J. P. / Álvarez, M. G. / Jiménez, C. / Medina, A. / Chillón, M. C. / Gazdova, J. / Blanco, Ó. / Díaz, L. G. / Villanueva, J. G. et al. | 2023
- 333
-
Personalized monitoring of circulating tumor DNA by a specific signature of trackable mutations after chimeric antigen receptor t‐cell therapy in non‐Hodgkin B cell lymphomaBastos, M. / Barrio, S. / Martin‐Muñoz, A. / de la iglesia, I. / Muñiz, P. / Dorado, S. / Bailen, R. / Poza, M. / Chicano, M. / Garcia‐Ortiz, A. et al. | 2023
- 334
-
LIQUID BIOPSY FOR EARLY, NON‐INVASIVE DIAGNOSIS OF EBV‐POSITIVE BURKITT LYMPHOMA IN RESOURCE LIMITED SETTINGSChamba, C. C. / Ntemi, P. / Schuh, A. / Cuts, A. / Balandya, E. / Vavoulis, D. / Dreau, H. / Burns, A. / Howard, K. / Rideout, K. et al. | 2023
- 335
-
Clinical impact of Epstein–Barr virus DNA in aggressive NK‐cell leukemiaFujimoto, A. / T., Maeda / Fukuhara, N. / Miyazaki, K. / Yamaguchi, M. / Ishida, F. / Suzuki, R. et al. | 2023
- 335
-
Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patientsDerenzini, Enrico / Gueli, Angela / Risso, Alessandra / Bruna, Riccardo / Gottardi, Daniela / Cignetti, Alessandro / Pileri, Stefano / Avvedimento, Enrico V. / Tarella, Corrado et al. | 2023
- 336
-
Molecular features possessed in the ctDNA reveal heterogeneity and predict outcome in newly diagnosed peripheral T‐cell lymphomaLiang, J. / Hua, W. / Shen, H. / Yin, H. / Wu, J. / Li, Y. / Wang, L. / Li, J. / Xu, W. et al. | 2023
- 338
-
Cell‐free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA studySako, N. / Delfau, M. / Bachy, E. / Morschhauser, F. / Cartron, G. / Casasnovas, O. / Gressin, R. / Daguindau, N. / Tournilhac, O. / Bouabdallah, K. et al. | 2023
- 339
-
The impact of spleen metabolic tumor volume on total metabolic tumor volume and prognosis in patients with follicular lymphoma enrolled in FOLL 12 trialGuerra, L. / Chauvie, S. / Marcheselli, L. / Bergesio, F. / Durmo, R. / Peano, S. / Franceschetto, A. / Fallanca, F. / Pinto, A. / Ghiggi, C. et al. | 2023
- 340
-
Comparison of machine learning approaches for POD24 prediction based on pretreatment PET in follicular lymphoma patients (on behalf of CALYM/LYSA groups)Hoang, D. T. / Schalck, E. / Ricci, R. / Chartier, L. / Marlot, L. / Gomez, E. / Nadel, B. / Xerri, L. / Morschhauser, F. / Kanoun, S. et al. | 2023
- 341
-
Automated FDG PET/CT radiomics for risk stratification in newly diagnosed diffuse large B‐cell lymphoma (DLBCL)Shreve, J. T. / Hazim, A. Z. / Bock, A. M. / Pritchett, J. C. / Maurer, M. J. / Shah, M. V. / Binder, M. / Witzig, T. E. / Wang, Y. / Nowakowski, G. S. et al. | 2023
- 342
-
An automated quantification algorithm for evaluating total metabolic tumor volume in patients with FDG‐avid lymphomas using a deep learning modelXu, T. / Jemaa, S. / Kumar, M. / Balasubramanian, S. / Shamas‐Din, A. / Lyalina, S. / Ounadjela, S. / Malik, B. / Lee, J. / Morales, S. Figueroa et al. | 2023
- 343
-
Impact of anti‐SARS‐CoV‐2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective studyAssanto, Giovanni Manfredi / Di Rocco, Alice / Malfona, Francesco / Capriata, Marcello / Del Giudice, Ilaria / Petrucci, Luigi / Girardi, Paola / D’Elia, Gianna Maria / Martelli, Maurizio / Gentile, Giuseppe et al. | 2023
- 344
-
Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory or early relapsing diffuse large B‐cell lymphoma (DLBCL)Bock, A. M. / Mwangi, R. / Ataei, F. / Thorpe, M. / Shreve, J. T. / Pritchett, J. C. / Maurer, M. J. / Paludo, J. / Cerhan, J. R. / Khurana, A. et al. | 2023
- 345
-
Differences in baseline PET/CT lymphoma distribution patterns between DLBCL‐NOS and high‐risk DLBCL patientsCroese, K. J. / Zwezerijnen, G. J. C. / Bes, A. L. / Wiegers, S. E. / Heymans, M. W. / Boellaard, R. / Lugtenburg, P. J. / Eertink, J. J. / Zijlstra, J. M. / Chamuleau, M. E. D. et al. | 2023
- 346
-
Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials—A LYSA retrospective analysisWillaume, A. / Chartier, L. / Ricci, R. / Blanc‐Durand, P. / Amorim, S. / Haioun, C. / Thieblemont, C. / Legouill, S. / Casasnovas, O. / Morschhauser, F. et al. | 2023
- 347
-
Modification of Lugano Criteria by Pre‐Infusion Tumor Kinetics Improves Early Survival Prediction for Lymphoma Patients Under Chimeric Antigen Receptor T‐Cell TherapyKunz, W. G. / Blumenberg, V. / Rejeski, K. / Buecklein, V. L. / Schmidt, C. / Dekorsy, F. J. / Bartenstein, P. / Ricke, J. / von Bergwelt‐Baildon, M. / Subklewe, M. et al. | 2023
- 349
-
Interim 3‐Dimensional volumetric response (3DVR) is associated with better overall survival of patients (pts) with primary central nervous system lymphoma (PCNSL)Martynchyk, A. / O'Shaughnessy, J. / Lee, S. / Chong, G. / Agrawal, S. / Tatarczuch, M. / Narisa, A. Azryn / Gregory, G. P. / Churilov, L. / Hawkes, E. A. et al. | 2023
- 349
-
Baseline PET Total Metabolic Tumor Volume has a prognostic role in PTCLs—Data from International Prospective T‐Cell Project 2.0Skrypets, T. / Chauvie, S. / Manni, M. / Fallanca, F. / Racca, M. / Hitz, F. / Advani, R. / Ramos, C. D. / Miranda, E. / Tomuleasa, C. et al. | 2023
- 350
-
Baseline‐PET derived metrics are the most relevant factors for risk stratification in early‐stage nonbulky HL: preliminary results of the RAFTING trialZaucha, J. M. / Picardi, M. / Kurlapski, M. / Patti, C. / Domingo‐Domenech, E. / Sanz, R. Garcia / Rossi, A. / Lopez‐jimenez, J. / Trentin, L. / Gotti, M. et al. | 2023
- 351
-
PET‐Adapted Therapy with Nivolumab plus Adriamycin, Vinblastine, and Dacarbazine for Newly Diagnosed Stage III or IV Hodgkin LymphomaMoskowitz, A. / Savage, K. / Feldman, T. / Ganesan, N. / Hancock, H. / Davey, T. / Perez, L. / Santarosa, A. / Subzwari, S. / Capadona, C. et al. | 2023
- 353
-
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early‐stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35‐027 Part C)Abramson, J. S. / Straus, D. / Bartlett, N. / Burke, J. M. / Lynch, R. C. / Domingo‐Domenech, E. / Hess, B. / Schuster, S. / Linhares, Y. / Ramchandren, R. et al. | 2023
- 354
-
Risk of a second cancer and infection in patients with indolent B‐cell lymphoma exposed to first‐line bendamustine plus rituximab: A retrospective analysis of an administrative claims databaseDote, Satoshi / Inose, Ryo / Goto, Ryota / Kobayashi, Yuka / Muraki, Yuichi et al. | 2023
- 355
-
Impact of PET‐2 guided treatment de‐escalation on time‐to‐recovery from cancer‐related fatigue in advanced stage Hodgkin Lymphoma: results from the GHSG HD18 studyFerdinandus, J. / Müller, H. / Damaschin, C. / Jacob, A. S. / Meissner, J. / Krasniqi, F. / Mey, U. / Schöndube, D. / Thiemer, J. / Mathas, S. et al. | 2023
- 356
-
Replacing procarbazine with dacarbazine in escalated BEACOPP reduces clinical toxicity with no loss of efficacy yet protects stem cells from excess somatic mutational damageSantarsieri, A. / Mitchell, E. / Sanghvi, R. / Lee‐Six, H. / Sturgess, K. / Brice, P. / Menne, T. / Osborne, W. / Creasey, T. / Ardesnhna, K. M. et al. | 2023
- 357
-
‘ACOPP’ chemotherapy for older and less fit patients with Hodgkin lymphoma—a multicentre, retrospective studyWilson, M. R. / Haynes, E. / Hopkins, D. / Robertson, E. / Parsons, K. / Ferguson, G. / Quinn, D. / Murray, J. / Osborne, W. / Leach, M. et al. | 2023
- 359
-
Brentuximab vedotin (BV) + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): incidence and management of peripheral neuropathy (PN) in a multi‐institution cohortBowers, J. T. / Anna, J. / Bair, S. M. / Annunzio, K. / Epperla, N. / Pullukkara, J. Joy / Gaballa, S. / Spinner, M. / Li, S. / Messmer, M. et al. | 2023
- 360
-
BEGEV as salvage regimen in first setting for relapsed/refractory classical Hodgkin lymphomaCarella, M. / Argnani, L. / Coppola, P. E. / Nanni, L. / Zoli, S. / Cantelli, M. / Morigi, A. / Gentilini, M. / Lolli, G. / Bagnato, G. et al. | 2023
- 361
-
Efficacy of brentuximab consolidation by metabolic response in an international real‐world cohort of classic Hodgkin lymphoma at high risk for progression after ASCTDesai, S. H. / Smith, A. / Spinner, M. / Sykorova, A. / Bachanova, V. / Evens, A. M. / Goyal, G. / Kahl, B. / Dorritie, K. / Azzi, J. et al. | 2023
- 363
-
Toxicities at one year follow‐up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study GroupFerdinandus, J. / Moccia, A. A. / Greil, R. / Hertzberg, M. / Schaub, V. / Hüttmann, A. / Keil, F. / Dierlamm, J. / Hänel, M. / Novak, U. et al. | 2023
- 363
-
Predictors of ibrutinib‐associated atrial fibrillation: 5‐year follow‐up of a prospective studyMattiello, Veronica / Barone, Angelica / Giannarelli, Diana / Noto, Alessandro / Cecchi, Nicola / Rampi, Nicolò / Cassin, Ramona / Reda, Gianluigi et al. | 2023
- 364
-
An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatmentLavie, D. / Johnson, N. / Borchmann, P. / Herrera, A. F. / Avigdor, A. / Gasiorowski, R. / Gregory, G. / Keane, C. / Vucinic, V. / Bazargan, M. et al. | 2023
- 364
-
Outpatient treatment with 2 cycles of Bendamustine, Gemcitabine and Dexamethasone is Effective and Safe in r/r Hodgkin Lymphoma—Polish Lymphoma Research Group StudyPaszkiewicz‐Kozik, E. / Kurlapski, M. / Swoboda, R. / Subocz, E. / Szymanski, M. / Taszner, M. / Wicherska‐Pawlowska, K. / Koclega, A. / Domanska‐Czyz, K. / Swierkowska, M. et al. | 2023
- 366
-
Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agentsDesai, S. H. / Spinner, M. / Evens, A. M. / Bachanova, V. / Goyal, G. / Kahl, B. / Dorritie, K. / Azzi, J. / Kenkre, V. P. / Arai, S. et al. | 2023
- 368
-
Role of autologous stem cell transplantation or salvage chemotherapy in relapsed/refractory classical Hodgkin lymphoma patients after immune checkpoint inhibitorsPellegrini, C. / Casadei, B. / Sutto, E. / Cantelli, M. / Argnani, L. / Broccoli, A. / Gugliotta, G. / Stefoni, V. / Nanni, L. / Carella, M. et al. | 2023
- 369
-
Secondary cancer is the leading cause of death 15 years or more after diagnosis of early‐stage Hodgkin lymphomaLagerlöf, I. / Fohlin, H. / Enblad, G. / Glimelius, B. / Goldkuhl, C. / Palma, M. / Glimelius, I. / Molin, D. et al. | 2023
- 370
-
Overall survival and causes of death in elderly patients with Hodgkin lymphoma—a Norwegian population‐based case‐control studyLia, K. / Jørgensen, R. R. K. / Wold, B. L. / Fluge, Ø. / Fagerli, U. / Bersvendsen, H. / Bø, I. B. / Bhargava, S. / Fosså, A. et al. | 2023
- 371
-
Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphomaGao, F. / Liu, H. / Wang, X. / Zhang, H. et al. | 2023
- 371
-
Malnutrition diagnosed by GLIM criteria better predicts long‐term outcomes for patients with non‐Hodgkin's lymphoma: A prospective multicenter cohort studyZou, Yuanlin / Xu, Hongxia / Lyu, Quanjun / Weng, Min / Cui, Jiuwei / Shi, Hanping / Song, Chunhua et al. | 2023
- 372
-
Real‐world treatment patterns and clinical outcomes among follicular lymphoma patients in the SEER‐Medicare populationChihara, D. / Yang, S. / Chawla, S. Bains / Zhang, G. / Wang, A. / Yu, J. / Arnette, D. / Navarro, F. Rivas / Blaedel, J. / Mutebi, A. et al. | 2023
- 373
-
Analysis of Real‐World Treatment Patterns and Outcomes Among Patients With Relapsed/Refractory Follicular Lymphoma Including POD24 PatientsSehn, L. H. / Wang, A. / Yu, J. / Kamalakar, R. / Sail, K. / Sinai, W. / Arnette, D. / Yang, S. / Mutebi, A. / Navarro, F. R. et al. | 2023
- 375
-
Real‐World Early Outcomes of Axicabtagene Ciloleucel for Relapsed or Refractory (R/R) Follicular Lymphoma (FL)Jacobson, C. / Hemmer, M. T. / Hu, Z. / Frank, M. / Popplewell, L. / Ahmed, N. / Lin, Y. / Best, T. / Beygi, S. / Miao, H. et al. | 2023
- 376
-
The prognostic value of progressing within 24 months of frontline chemoimmunotherapy (POD24) in relapsed/refractory (R/R) follicular lymphoma (FL)—a SCHOLAR‐5 analysisPatel, A. R. / Limbrick‐Oldfield, E. H. / Kanters, S. / Ray, M. D. / Best, T. / Ghione, P. / Neelapu, S. S. / Gribben, J. G. / Beygi, S. / Bobillo, S. et al. | 2023
- 378
-
Prognostic value of the end of induction PET in patients with follicular lymphoma: results from the analysis of FOLL 12 trialGuerra, L. / Bergesio, F. / Fallanca, F. / Chauvie, S. / Marcheselli, L. / Durmo, R. / Peano, S. / Franceschetto, A. / Pinto, A. / Tani, M. et al. | 2023
- 378
-
Treatment outcomes of Limited Stage Grade 3A Follicular LymphomaSarkar, R. R. / Lee, J. / Zhang, Z. / Zelenetz, A. / Salles, G. / Yahalom, J. / Imber, B. et al. | 2023
- 380
-
Outcomes in primary gastrointestinal (GI) follicular lymphoma (FL): results from a multicenter analysisSt‐Pierre, F. / Alrifai, T. / Alhamad, K. / McCall, B. / Annunzio, K. / Mi, X. / Doukas, P. G. / Schoen, A. / Fu, L. / Au, C. et al. | 2023
- 380
-
Prognostic value of prognostic nutritional index on extranodal natural killer/T‐cell lymphoma patients: A multicenter propensity score matched analysis of 1022 cases in Huaihai Lymphoma Working GroupShen, Ziyuan / Zhang, Shuo / Chen, Xicheng / Zhang, Qing / Jiao, Yaxue / Shi, Yuye / Zhang, Hao / Ye, Jingjing / Wang, Ling / Zhu, Taigang et al. | 2023
- 381
-
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular LymphomaUjjani, C. / Wang, H. / Broome, C. / Gopal, A. / Lai, C. / Warren, E. / Shadman, M. / Smith, S. D. / Lynch, R. / Swanson, N. et al. | 2023
- 383
-
A Phase II Investigator Initiated Study of Acalabrutinib, Lenalidomide and Rituximab (aR2) in Patients with Previously Untreated High Tumor Burden Follicular LymphomaStrati, P. / Feng, L. / Westin, J. / Nair, R. / Gouni, S. / Fayad, L. / Rodriguez, M. / Chihara, D. / Malpica, L. / Steiner, R. et al. | 2023
- 383
-
Outpatient administration of mosunetuzumab in US community practice settings: perspectives and learnings from the Phase II MorningSun studyFlinn, I. W. / Sharman, J. / Liu, S. / Gandhi, M. / Anz, B. / Biondo, J. M. L. / Jani, P. / Wu, M. / Lin, T. / Parmar, N. et al. | 2023
- 385
-
The impact of CHOP versus bendamustine on bone mineral density in patients with follicular lymphoma enrolled in the GALLIUM studyPedersen, M. A. / Gormsen, L. C. / Jakobsen, L. H. / Eyre, T. A. / Severinsen, M. T. / Baech, J. / Dann, E. J. / Knapp, A. / Sahin, D. / Vestergaard, P. et al. | 2023
- 386
-
Evaluation of the GELTAMO guidelines for surveillance in follicular lymphomas after first‐line immunochemotherapy: a real‐world prospective studyLlodrà, M. A. / Marino, S. F. Pinzón / Díez‐Feijoo Varela, R. / Lafuente, M. / Sánchez‐González, B. / Maiques, J. M. / Silvestre, A. Salar et al. | 2023
- 387
-
REALMA: Subset of patients with Marginal Zone Lymphomas from the French nationwide REALYSA real‐world prospective cohort.Bommier, C. / Donzel, M. / Rossi, C. / Fornecker, L. / Bijou, F. / Chauchet, A. / Lebras, L. / Ysebaert, L. / Haioun, C. / Bouabdallah, K. et al. | 2023
- 388
-
Matching‐adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)Thieblemont, C. / Wang, K. / Keeping, S. / Zhang, I. / Yang, K. / Tang, B. / Mohseninejad, L. et al. | 2023
- 389
-
Lenalidomide treatment for recurrent adult T‐cell leukemia/lymphoma after allogeneic hematopoietic cell transplantationTanaka, Takashi / Inamoto, Yoshihiro / Ito, Ayumu / Watanabe, Mizuki / Takeda, Wataru / Aoki, Jun / Kim, Sung‐Won / Fukuda, Takahiro et al. | 2023
- 389
-
Orelabrutinib, a new‐generation bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphomaSong, Y. / Li, Z. / Zhang, H. / Liu, L. / Hu, J. / Huang, H. / Liu, T. / Jin, J. / Li, W. / Huang, Z. et al. | 2023
- 390
-
Long‐term efficacy and safety of zanubrutinib (ZANU) in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB‐3111‐214) trialTrotman, J. / Tedeschi, A. / Hu, B. / Linton, K. M. / McKay, P. / Leitch, S. / Jin, J. / Sun, M. / Sobieraj‐Teague, M. / Zinzani, P. L. et al. | 2023
- 393
-
A single‐center experience of low‐dose radiotherapy for primary extranodal marginal zone lymphoma of bronchus‐associated lymphoid tissue (BALT)Freret, M. E. / Tringale, K. R. / Imber, B. S. / Joffe, E. / Yahalom, J. / Hajj, C. et al. | 2023
- 394
-
CLinicopathological characteristics of extranodal marginal zone B‐cell lymphoma of the intestine: a single center analysisSteinbrecher, O. / Kiesewetter, B. / Dolak, W. / Simonitsch‐Klupp, I. / Raderer, M. et al. | 2023
- 394
-
Autologous and allogeneic stem‐cell transplantation for transformed Waldenström macroglobulinemiaDurot, E. / Kanagaratnam, L. / Zanwar, S. / Kaufman, A. / D'Sa, S. / Toussaint, E. / Roos‐Weil, D. / Alcoceba, M. / Vos, J. M. / Hivert, B. et al. | 2023
- 396
-
Efficacy and safety of PD‐1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective studyTian, Jing / Hao, Miaowang / Liu, Qiang / Xiao, Fang / Li, Yuanchun / Qi, Meiying / Gao, Jing / Liu, Li / Yin, Dandan et al. | 2023
- 396
-
Indolent lymphoma: Bendamustine, rituximab and acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM)Berinstein, N. L. / Roos, K. / Klein, G. / McClure, R. / Forward, N. / Shafey, M. / Nikonova, A. / MacDonald, D. / Villa, D. / Sandhu, I. et al. | 2023
- 397
-
Single‐agent rituximab as an effective salvage therapy in pre‐treated hairy cell leukemiaBroccoli, A. / Argnani, L. / Nanni, L. / Lolli, G. / Stefoni, V. / Zoli, S. / Cantelli, M. / Pellegrini, C. / Morigi, A. / Gentilini, M. et al. | 2023
- 397
-
Intralesional rituximab in the treatment of primary cutaneous B‐cell lymphomas: a single‐center experienceRampi, N. / Muniesa, C. / Pereira, P. Lopez / Climent, F. / Frias‐Gomez, J. / Barca, E. Gonzalez / Oliveira, A. C. / Aguilera, C. / Sureda, A. / Servitje, O. et al. | 2023
- 399
-
Patterns of disease failure by response to induction therapy in a large cohort of patients with primary central nervous system lymphomaTringale, K. R. / Yahalom, J. / Scordo, M. / White, C. / Zhang, Z. / Grommes, C. / Imber, B. et al. | 2023
- 400
-
Ibrutinib in Combination with Ifosfamide, Etoposide, and Rituximab Followed by Ibrutinib Maintenance Therapy in Patients with R/R‐PCNSL: A Multicenter Phase II StudyChoi, Y. S. / Song, G. / Baek, D. W. / Yoon, S. E. / Kang, K. / Yhim, H. / Oh, S. Y. / Jeong, S. H. / Kim, S. J. / Kim, H. J. et al. | 2023
- 401
-
Induction (MATRix) Followed by Transplantation in Primary Central Nervous System Lymphoma. Experience of the GELTAMO (Grupo Español de Linfoma y Trasplante de Medula Ósea)Lopez‐Pereira, P. / Romero‐Dominguez, S. / Martin‐Moro, F. / Caballero‐Gonzalez, A. C. / Lopez‐Garcia, A. / Cruz‐Benito, B. de la / Franch‐Sarto, M. / Cruz‐Vicente, F. de la / Lopez‐Marin, J. / Pinzon‐Marino, S. et al. | 2023
- 401
-
Evolving consolidation patterns and modern outcomes for a large longitudinal cohort of primary CNS lymphoma patientsImber, B. S. / Tringale, K. / White, C. / Zhang, Z. / Scordo, M. / Yahalom, J. / Grommes, C. et al. | 2023
- 403
-
Bone Marrow Assessment may be Omitted in Newly Diagnosed Diffuse Large B‐Cell Lymphomas with Primary CNS InvolvementMartin‐Moro, F. / Lopez‐Pereira, P. / Marquet‐Palomanes, J. / Bento, L. / Salar, A. / Sancho, J. M. / Gonzalez‐Villambrosia, S. / Lario‐Arribas, A. / Sanchez‐Pina, J. M. / Garcia, D. et al. | 2023
- 404
-
Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphomaYi, J. H. / Kim, S. J. / Yang, D. / Do, Y. R. / Won, J. H. / Baek, D. / Shin, H. J. / Kim, D. S. / Kim, H. J. / Kang, K. et al. | 2023
- 405
-
Preliminary results of penpulimab combined with RMA (rituximab, methotrexate, and cytarabine) for newly diagnosed primary central nervous system lymphoma (PCNSL)Shen, H. / Wu, J. / Liang, J. / Yin, H. / Wang, L. / Li, J. / Xu, W. et al. | 2023
- 406
-
Radiotherapy as an effective bridge for chemo‐refractory or progressive secondary CNS lymphomaCederquist, G. / Tringale, K. / Hajj, C. / Hubbeling, H. / Sarkar, R. / Ma, J. / Dreyfuss, A. / Fregonese, B. / Lee, J. / Salles, G. et al. | 2023
- 407
-
Geriatric assessment scores: Predictors of prognosis and premature end of treatment in the MARTA and MARiTA study population of elderly PCNSL patients >65 yearsIsbell, L. K. / Vreden, A. / Ihorst, G. / Uibeleisen, R. / Friedl, A. / Orban, A. / Malenica, N. / Fricker, H. / Wendler, J. / Neumaier, S. et al. | 2023
- 407
-
Long‐term outcomes in Hodgkin lymphoma survivors. Temporary trends and comparison with general populationNúñez‐García, Beatriz / Clemente, Mariola Blanco / Sánchez, Juan Cristóbal / Royuela, Ana / Ibargüen, Blanca Cantos Sánchez de / Méndez, Miriam / López‐Ibor, Jorge V. / Martínez, Marta / Traseira, Cristina / Garitaonaindia, Yago et al. | 2023
- 408
-
Primary Mediastinal B‐cell Lymphoma, a nationwide real‐life retrospective study from Fondazione Italiana Linfomi (FIL)Iannitto, E. / Balzarotti, M. / Martelli, M. / Zinzani, P. / Tucci, A. / Di Rocco, A. / Cavallo, F. / Usai, S. V. / Guidetti, A. / Ravano, E. et al. | 2023
- 410
-
REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTSVassilakopoulos, T. / Ferhanoglu, B. / Horowitz, N. / Mellios, Z. / Kaynar, L. / Zektser, M. / Symeonidis, A. / Piperidou, A. / Giotas, A. / Agathocleous, A. et al. | 2023
- 411
-
Axicabtagene ciloleucel (Axicel) for relapsed/refractory primary mediastinal B‐cell lymphoma (r/r PMBCL) compared to DLBCL‐NOS: A GLA/DRST registry study.Schubert, M. / Ayuk, F. A. / Bethge, W. / von Bonin, M. / Vucinic, V. / Wagner‐Drouet, E. M. / Subklewe, M. / Baldus, C. D. / Glass, B. / Marks, R. et al. | 2023
- 412
-
Primary lymphoma of the female genital tract: a retrospective survey of the International Extranodal Lymphoma Study Group (IELSG35)Steffanoni, S. / Vanazzi, A. / Esposito, F. / Cabrera, M. E. / Akhtar, S. S. / Gardella, S. / Bairey, O. / Pavlovsky, A. / Polino, A. / Landi, F. et al. | 2023
- 413
-
Comparison Between aaIPI, LAB‐PI, NCCN‐IPI and GELTAMO‐IPI to Predict Prognosis in Elderly Patients with Diffuse Large‐B Cell Lymphoma who Undergo R‐CHOP/R‐miniCHOPMartin‐Moro, F. / Marquet‐Palomanes, J. / Bento, L. / Diaz‐Lopez, A. / Garcia‐Vela, J. A. / Sanchez‐Pina, J. M / Cordoba, R. / Salar, A. / Novelli, S. / Rodriguez‐Salazar, M. J. et al. | 2023
- 414
-
Patient‐ versus clinician‐reported symptoms in the POLARIX studyThompson, C. A. / Mehta‐Shah, N. / Flowers, C. / Salles, G. / Tilly, H. / Chua, N. / Casasnovas, R. / Miall, F. / Kim, T. M. / Tsai, C. et al. | 2023
- 415
-
Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trialBiggi, Alberto / Chauvie, Stephane / Fallanca, Federico / Guerra, Luca / Bergesio, Fabrizio / Menga, Massimo / Bianchi, Andrea / Gregianin, Michele / Chiaravalloti, Agostino / Schillaci, Orazio et al. | 2023
- 416
-
Subgroup analysis of elderly patients (pts) with diffuse large B‐cell lymphoma (DLBCL) in the Phase 3 POLARIX studyHu, B. / Reagan, P. M. / Sehn, L. H. / Sharman, J. / Hertzberg, M. / Zhang, H. / Kim, A. / Herbaux, C. / Molina, L. / Maruyama, D. et al. | 2023
- 418
-
A Retrospective Analysis of Clinical Characteristics, Treatment, and Outcomes in Large B‐cell Lymphomas with Synchronous Systemic and Central Nervous System InvolvementHaydu, J. E. / Redd, R. A. / Lei, M. / Karschnia, P. / Dietrich, J. M. / Nayak, L. / Abramson, J. S. et al. | 2023
- 420
-
Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk diffuse large B‐cell lymphomaLenz, G. / Tilly, H. / Ziepert, M. / Altmann, B. / Craine, V. / Yan, M. / Herbaux, C. / Frontzek, F. / Nickelsen, M. / Hirata, J. et al. | 2023
- 421
-
Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITIONMinson, A. / Verner, E. / Giri, P. / Wong, S. M. / Ratnasingam, S. / Butler, J. / Janowski, W. / Ku, M. / Cheah, C. Y. / Hertzberg, M. et al. | 2023
- 422
-
Zanbrutinib, lenalidomide plus R‐CHOP (ZR2‐CHOP) as the first‐line treatment for non‐GCB diffuse large B‐cell lymphoma: An updated analysis of efficacy and tolerabilityZhu, H. / Xia, Y. / Sha, Y. / Miao, Y. / Qin, S. / Wu, W. / Ding, C. / Wang, Z. / Fan, L. / Xu, W. et al. | 2023
- 424
-
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide‐treated myeloma patientsAsano, Arisa / Ri, Masaki / Masaki, Ayako / Maeda, Yasuhiro / Tachita, Takuto / Hirade, Kentaro / Marumo, Yoshiaki / Nakashima, Takahiro / Hagiwara, Shinya / Kinoshita, Shiori et al. | 2023
- 424
-
Ibrutinib + bortezomib + R‐CHOP for higher‐risk DLBCL: Feasibility, efficacy and molecular predictorsDenker, S. / Bittner, A. / Frick, M. / Kase, J. / Hoffmann, J. / Trenker, C. / Keller, U. / Bogner, C. / Hüttmann, A. / Dürig, J. et al. | 2023
- 425
-
Pixantrone containing R‐CPOP as firstline treatment in elderly DLBCL patients with congestive heart failure or high risk of anthracycline induced cardiotoxicityMarks, R. / Lorenz, K. / Trepel, M. / Rank, A. / Illerhaus, G. / Pelz, H. / Scholz, C. / Duyster, J. / Strüßmann, T. et al. | 2023
- 426
-
Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCLVerner, E. / Johnston, A. / Pati, N. / Hawkes, E. / Lee, H. P. / Cochrane, T. / Cheah, C. Y. / Filshie, R. / Purtill, D. / Sia, H. et al. | 2023
- 427
-
The treatment of Burkitt lymphoma with the Berlin‐Frankfurt‐Münster protocol with rituximab and autologous transplantationBroccoli, A. / Argnani, L. / Gugliotta, G. / Stefoni, V. / Pellegrini, C. / Casadei, B. / Nanni, L. / Coppola, P. E. / Sutto, E. / Cantelli, M. et al. | 2023
- 428
-
Quality of life and response shift effect of diffuse large B‐cell lymphoma French patients included in prospective real‐life REALYSA cohort in the first year after diagnosisAnota, A. / Basset, M. / Belot, A. / Bascoul‐Mollevi, C. / Cottone, F. / Efficace, F. / Préau, M. / Touraine, C. / Damaj, G. / Guidez, S. et al. | 2023
- 429
-
Trends in relative survival of Diffuse large B‐cell lymphoma in Sweden in the era of targeted and cellular therapiesSmedby, K. Ekström / Antonilli, S. / Enblad, G. / Sonnevi, K. / Wahlin, B. E. / Andersson, P. / Jerkeman, M. / Eloranta, S. et al. | 2023
- 430
-
Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival OutcomesBock, A. M. / Mwangi, R. / Wang, Y. / Khurana, A. / Maurer, M. J. / Ayers, A. / Kahl, B. / Martin, P. / Cohen, J. / Casulo, C. et al. | 2023
- 432
-
Cause of death and prognosis of patients (pts) with primary refractory disease, and prognosis of pts reaching PFS24: Descriptive analysis of POLARIXHerbaux, C. / Dietrich, S. / McMillan, A. / Thieblemont, C. / Gonzalez‐Barca, E. / Pinto, A. / Fogliatto, L. / Matasar, M. / Lee, C. / Hernandez, J. et al. | 2023
- 433
-
Comparison of clinical outcomes in patients with relapsed/refractory large B‐cell lymphoma treated with epcoritamab versus chemoimmunotherapyIp, A. / Rosenthal, A. / Mutebi, A. / Wang, T. / Jun, M. / Wang, A. / Yu, J. / Brodkin, S. / Sacchi, M. / Kalsekar, A. et al. | 2023
- 434
-
Novel therapies for the treatment of relapsed‐refractory aggressive B‐cell lymphoma increase survival. Analysis from the RELINF registry of the GELTAMO groupBastos‐Oreiro, M. / Abrisqueta, P. / Gutierrez, A. / Jimenez‐Ubieto, A. / Gonzalez de Villambrosia, S. / Córdoba, R. / López, A. / Poza, M. / Ceballos, E. Pérez / Navarro, B. et al. | 2023
- 434
-
Diagnostic relevance of 2‐[18F]‐FDG PET/CT in patients recently diagnosed with monoclonal gammopathy of undetermined significanceRudolphi‐Solero, Teodoro / Triviño‐Ibáñez, Eva María / González‐Jiménez, Antonio Daniel / Ramos‐Font, Carlos / Ríos‐Tamayo, Rafael / Rebollo‐Aguirre, Angel Custodio / Sánchez‐Sánchez, Rocío et al. | 2023
- 436
-
Venetoclax combined with R‐ICE (VICER) for second line treatment of diffuse large B cell lymphoma refractory or relapsed after initial chemoimmunotherapyCaimi, P. F. / Cashen, A. / Gallogly, M. / Winter, A. / Boughan, K. / Ghobadi, A. / Jagadeesh, D. / Cooper, B. / Mehta‐Shah, N. / Dean, R. et al. | 2023
- 437
-
Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR)Fornecker, L. / Delwail, V. / Thieblemont, C. / Ghesquieres, H. / Bouabdallah, K. / Tilly, H. / Le Calloch, R. / Morschhauser, F. / Costello, R. / Slama, B. et al. | 2023
- 437
-
Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND studyDuell, J. / Abrisqueta, P. / Andre, M. / Augustin, M. / Gaidano, G. / Barca, E. G. / Jurczak, W. / Kalakonda, N. / Liberati, A. M. / Maddocks, K. J. et al. | 2023
- 439
-
Five‐year subgroup analysis of tafasitamab + lenalidomide from the Phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphomaDuell, J. / Abrisqueta, P. / Dreyling, M. / Gaidano, G. / Barca, E. G. / Jurczak, W. / Maddocks, K. J. / Menne, T. / Nagy, Z. / Tournilhac, O. et al. | 2023
- 441
-
Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND)Sehn, L. H. / Kuruvilla, J. / Salles, G. / Maddocks, K. J. / Koch, C. / Xue, Z. / Amoloja, T. / Amin, A. / Duell, J. et al. | 2023
- 442
-
Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs studySunami, Kazutaka / Fuchida, Shin‐ichi / Suzuki, Kenshi / Ri, Masaki / Matsumoto, Morio / Shimazaki, Chihiro / Asaoku, Hideki / Shibayama, Hirohiko / Ishizawa, Kenichi / Takamatsu, Hiroyuki et al. | 2023
- 443
-
Interim report from a phase 2 multicenter study of anti‐PD‐1 antibody (penpulimab) plus lenalidomide, rituximab, gemcitabine and oxaliplatin in Relapsed/ Refractory DLBCLLiang, J. / Wang, F. / Shen, H. / Yin, H. / Wu, J. / Li, Y. / Wang, L. / Li, J. / Gu, W. / Xu, W. et al. | 2023
- 443
-
Combination of acalabrutinib with rituximab and lenalidomide in relapsed/refractory B cell non‐Hodgkin lymphomaPark, C. / Lee, H. S. / Kang, K. / Lee, W. / Do, Y. R. / Kwak, J. / Shin, H. / Kim, S. / Yi, J. H. / Lim, S. N. et al. | 2023
- 445
-
Predictors of long‐term survival outcomes following receipt of autologous stem cell transplantation for patients with diffuse large/high grade B cell lymphomaLandsburg, D. J. / Nasta, S. D. / Svoboda, J. / Schuster, S. J. / Gerson, J. N. / Chong, E. A. / Barta, S. K. / Cunningham, K. / Garfall, A. L. / Stadtmauer, E. A. et al. | 2023
- 447
-
Autologous hematopoietic cell transplantation (autoHCT) for T‐cell/histiocyte‐rich large B‐cell lymphoma (THRLBCL): An EBMT Lymphoma Working Party studyRenders, S. / Finel, H. / Ngoya, M. / Boumendil, A. / Schaap, N. / Ghesquieres, H. / Bloor, A. / Pérez‐Simón, J. A. / Huynh, A. / Kobbe, G. et al. | 2023
- 448
-
Outcomes of diffuse large/high grade B cell lymphoma patients following receipt of autologous stem transplantation or chimeric antigen receptor‐modified T cellsLandsburg, D. J. / Nasta, S. D. / Svoboda, J. / Gerson, J. N. / Schuster, S. J / Barta, S. K / Chong, E. A. / Difilippo, H. / Weber, E. / Cunningham, K. et al. | 2023
- 449
-
Prognostic factors for cellular therapies ‐ CART and allogeneic SCT ‐ in relapsed /refractory large B cell lymphoma (LBCL)Glass, B. / Sureda, A. / Boumendil, A. / Dreger, P. / Corradini, P. / Ram, R. / Kroeger, N. / Castagna, L. / Pabst, T. / Kwon, M. et al. | 2023
- 451
-
Comparison of overall survival of lisocabtagene maraleucel (liso‐cel) versus standard of care (SOC) adjusting for crossover in second‐line (2L) R/R large B‐cell lymphomaMorschhauser, F. / Ghesquieres, H. / Kamdar, M. / Liu, F. F. / Chandler, C. / Crotta, A. / Klijn, S. L. / Elsada, A. / Previtali, A. / Chaillol, I. et al. | 2023
- 452
-
CAR T treatment access and outcomes in patients with large B‐cell lymphoma according to ethnicity and socioeconomic deprivationDragoi, D. / Cusworth, S. / Amrith, M. / Sanderson, R. / Paneesha, S. / Patten, P. / Potter, V. / Hardefeldt, P. / Yallop, D. / Chaganti, S. et al. | 2023
- 453
-
Efficacy of Subcutaneous Epcoritamab versus Axi‐cel in R/R DLBCL CAR T‐Naive and CAR T‐eligible patients: An Indirect ComparisonThieblemont, C. / Fox, C. P. / Wang, A. / Sail, K. / Alshreef, A. / Moran, M. / Mutebi, A. / Blaedel, J. / Chirikov, V. / Salles, G. et al. | 2023
- 453
-
Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myelomaKauer, Joseph / Sester, Lilli Sophie / Kriegsmann, Katharina / Weinhold, Niels / Ober, Michael / Müller‐Tidow, Carsten / Goldschmidt, Hartmut / Raab, Marc‐Steffen / Sauer, Sandra et al. | 2023
- 454
-
Efficacy and toxicity of CAR T‐cell therapy in patients with primary and secondary central nervous system lymphoma—an analysis of the EBMT Lymphoma WP and the GoCART coalitionLaube, A. / Fuhrmann, S. / Peczynski, C. / Boumendil, A. / Michel, E. / Finel, H. / Galimard, J. / Beauvais, D. / Daskalakis, M. / Novak, U. et al. | 2023
- 456
-
Treatment with anti CD19 CAR‐T cells is safe and effective in patients with relapsed refractory large B‐cell lymphoma with active central nervous system involvementMarieton, E. Robin / Le Bras, F. / Malfuson, J. / Camus, V. / Legendre, H. / Degoutte, C. / Gounot, R. / Belhadj, K. / Sibon, D. / Dupuis, J. et al. | 2023
- 457
-
Efficacy and safety of Axicabtagene ciloleucel (Axi‐cel) for the treatment of relapse/refractory non‐Hodgkin lymphoma: First real‐world data in Chinese populationZhao, W. L. / Li, Y. H. / Zou, D. H. / Zhu, X. J. / Ji, D. M. / Qian, W. B. / Lu, Y. / Ji, C. Y. / Zhou, K. S. / Jing, H. M. et al. | 2023
- 458
-
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment for chronic lymphocytic leukemia/ small lymphocytic leukemia: a single‐arm studyYi, M. / Xia, Y. / Sha, Y. / Qin, S. / Jiang, R. / Qiu, T. / Wu, W. / Qiu, J. / Yang, Y. / Ding, C. et al. | 2023
- 459
-
Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B‐cell malignancies: Post hoc analysis of a large clinical trial safety databaseBrown, J. R. / Eichorst, B. / Ghia, P. / Jurczak, W. / Kahl, B. S. / Lamanna, N. / Robak, T. / Shadman, M. / Tam, C. S. / Qiu, L. et al. | 2023
- 461
-
Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trialsTedeschi, A. / Ahn, I. E. / Fraser, G. A. M. / Greil, R. / Munir, T. / Kay, N. E. / Flinn, I. W. / Lee, S. / Saifan, C. / Kearbey, J. et al. | 2023
- 463
-
Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): Impact on health‐related quality of lifeEichhorst, B. / Lamanna, N. / O'Brien, S. M. / Tam, C. S. / Qiu, L. / Yang, K. / Wu, K. / Salmi, T. / Barnes, G. / Brown, J. R. et al. | 2023
- 463
-
Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromesLee, Wan‐Hsuan / Lin, Chien‐Chin / Wang, Yu‐Hung / Yao, Chi‐Yuan / Kuo, Yuan‐Yeh / Tseng, Mei‐Hsuan / Peng, Yen‐Ling / Hsu, Cheng‐An / Sun, Hsun‐I / Chuang, Yi‐Kuang et al. | 2023
- 464
-
Ibrutinib (Ibr) for treatment of relapsed‐refractory (R/R) chronic lymphocytic leukemia (CLL): a matching‐adjusted indirect comparison of 3 randomized phase 3 trialsGhia, P. / Munir, T. / Burger, J. / Seymour, J. F. / Rogers, K. / Huang, H. / Moreno, C. / Neumayr, L. / Abbazio, C. / Sharman, J. et al. | 2023
- 466
-
Initial results of a multicenter phase 2 study of venetoclax in combination with R‐CHOP (VR‐CHOP) for patients with Richter SyndromeDavids, M. S. / Rogers, K. A. / Jain, N. / Tyekucheva, S. / Ren, Y. / Carey, C. / Montegaard, J. / Hajdenberg, M. / Ryan, C. E. / Merryman, R. et al. | 2023
- 468
-
Safety of acalabrutinib treatment in very old (≥80 y) and/or frail patients with chronic lymphocytic leukemia ‐ interim safety analysis of the ongoing phase II CLL‐Frail trialSimon, F. / Ligtvoet, R. / Nösslinger, T. / Bohn, J. / von Tresckow, J. / Liersch, R. / Gaska, T. / Jentsch‐Ullrich, K. / Koenigsmann, M. / Wolff, T. et al. | 2023
- 469
-
A phase 2 study of zanubrutinib in previously treated B‐cell malignancies intolerant to ibrutinib and/or acalabrutinib: Preliminary results for patients with CLL/SLLShadman, M. / Burke, J. M. / Zafar, S. F. / Misleh, J. / Rao, S. S. / Farber, C. M. / Cohen, A. / Crescenzo, R. / By, K. / Flinn, I. W. et al. | 2023
- 471
-
Timing of disease progression and impact on survival in Swedish mantle cell lymphoma patients—a novel illness‐death model studyEkberg, S. / Glimelius, I. / Albertsson‐Lindblad, A. / Weibull, C. E. et al. | 2023
- 472
-
Multicohort Study of Conditional Survival and Cause of Death After Achieving Event‐Free Survival at 24 Months (EFS24) in Patients With Mantle Cell Lymphoma (MCL)Wang, Y. / Larson, M. C. / Ekberg, S. / Smedby, K. E. / Zhao, E. J. / Gerrie, A. S. / Farooq, U. / Maurer, M. J. / Paludo, J. / Nowakowski, G. S. et al. | 2023
- 474
-
Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD studyVisco, C. / Malinverni, C. / Florea, E. / Glimelius, I. / Mirandola, M. / Ekström‐Smedby, K. / Tisi, M. C. / Giné, E. / Albertsson‐Lindblad, A. / Niebla, A. Marin et al. | 2023
- 474
-
Heat shock protein 90 inhibitors induce cell differentiation via the ubiquitin‐dependent aurora kinase A degradation in a MPLW515L mouse model of primary myelofibrosisWang, Fuping / Zhang, Haotian / He, Binghong / Liu, Zihan / Wu, Xinxin / Liu, Yuankai / Xu, Xin / Gou, Xiaoxue / Wang, Haitao / Yang, Qiong et al. | 2023
- 475
-
Secondary malignancies in mantle cell lymphoma patients—A nationwide population‐based study in SwedenAbalo, K. / Smedby, K. E. / Ekberg, S. / Eloranta, S. / Pahnke, S. / Albertsson‐Lindblad, A. / Jerkeman, M. / Glimelius, I. et al. | 2023
- 476
-
How to choose between curative radiotherapy or chemotherapy in low stage MCL?—a population‐based analysis of outcome in patients with stage I‐II MCL in SwedenAlbertsson‐Lindblad, A. / Ekberg, S. / Glimelius, I. / Ellin, F. / Sonnevi, K. / Lewerin, C. / Smedby, K. E. / Jerkeman, M. et al. | 2023
- 477
-
Enhanced ctDNA Profiling Reveals Molecular Determinants of Response and Resistance in Relapsed and Refractory Mantle Cell Lymphoma (NLG‐MCL7‐VALERIA)Meriranta, L. / Kolstad, A. / Hutchings, M. / Pasanen, A. / Niemann, C. Utoft / Riise, J. / Christensen, J. Haaber / Wader, K. Fahl / Glimelius, I. / Leppä, S. et al. | 2023
- 478
-
Long term follow‐up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combinationLe Gouill, S. / Morschhauser, F. / Chiron, D. / Bouabdallah, K. / Cartron, G. / Casasnovas, O. / Rule, S. / Bodet‐Milin, C. / Herbaux, C. / Gastinne, T. et al. | 2023
- 480
-
Long‐term safety with ≥12 months of pirtobrutinib in relapsed/refractory B‐cell malignanciesWang, Y. / Coombs, C. C. / Shah, N. N. / Jurczak, W. / Woyach, J. / Cheah, C. Y. / Patel, K. / Maddocks, K. / Muehlenbein, C. E. / Wang, C. et al. | 2023
- 481
-
Long‐term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.Carras, S. / Torroja, A. / Emadali, A. / Daguindau, N. / Tempescul, A. / Macro, M. / Moreau, A. / Tchernonog, E. / Houot, R. / Schmitt, A. et al. | 2023
- 483
-
Rituximab combined with chemotherapy and acalabrutinib prior to autologous stem cell transplantation in mantle cell lymphoma: The Rectangle TrialVilla, D. / Larouche, J. F. / Cheung, M. / Keating, M. M. / Zukotynski, K. / Tonseth, P. / Mayo, S. / Laister, R. / Scott, D. / Kuruvilla, J. et al. | 2023
- 484
-
Venetoclax based combination therapy does not overcome poor outcomes in BTKi‐refractory mantle cell lymphoma: phase 2 trial of umbralisib, ublituximab, and venetoclaxWallace, D. S. / Rowland, C. / Hill, B. T. / Baran, A. M. / Casulo, C. / Reagan, P. M. / Winter, A. / Karmali, R. / Winter, J. N. / Gordon, L. I. et al. | 2023
- 486
-
Analysis of immune and high‐risk biomarkers in patients with relapsed or refractory mantle cell lymphoma treated with glofitamab monotherapyPham*, T. H. / Leung*, W. / Hamidi, H. / Dickinson, M. / Morschhauser, F. / Carlo‐Stella, C. / Humphrey, K. / Mulvihill, E. / Lundberg, L. / Filezac de L’Etang, A. et al. | 2023
- 487
-
Using natural killer cell‐derived exosomes as a cell‐free therapy for leukemiaSamara, Aladin / Anbar, Michael / Shapira, Saar / Zemlyansky, Anna / Zozovsky, Alla / Raanani, Pia / Granot, Galit / Rozovski, Uri et al. | 2023
- 488
-
Real‐world outcomes of brexucabtagene autoleucel (brexu‐cel) for relapsed or refractory mantle cell lymphoma (r/r MCL): A CIBMTR subgroup analysis by prior treatmentAhmed, N. / Kambhampati, S. / Hamadani, M. / Grover, N. / Shadman, M. / Locke, F. L. / Gerson, J. / Frank, M. J. / Budde, L. E. / Wang, M. et al. | 2023
- 490
-
Outcomes of Bridging and Salvage Radiotherapy in Relapsed or Refractory Mantle Cell Lymphoma Patients Undergoing CD19‐Targeted CAR T‐Cell TherapyAbabneh, H. S. / Frigault, M. / Patel, C. G. et al. | 2023
- 491
-
Long term outcome of Peripheral T Cell Lymphomas: 10y follow‐up analysis of the International Prospective T Cell Project NetworkCivallero, M. / Advani, R. / Horwitz, S. / Manni, M. / Cabrera, M. E. / Vose, J. / Spina, M. / Hits, F. / Nagler, A. / Montoto, S. et al. | 2023
- 492
-
Diagnosis and management of adult T‐cell leukemia/lymphoma in a Brazilian Cohort. T‐cell Brazil ProjectChiattone, C. S. / Miranda, E. C. M. / Gonzaga, Y. B. M. / Baptista, R. L. R. / Dias, M. / Nogueira, F. L. / Borducchi, D. / Bellesso, M. / Duffles, G. / Pereira, J. et al. | 2023
- 493
-
Newly diagnosed extranodal natural killer/T cell lymphoma (ENKTL) treated by anti‐PD‐1 antibody plus histone deacetylase inhibitor followed by P‐GemOx regimenGao, Y. / Zhang, Y. / Wang, X. / Bai, B. / Zhang, X. / Huang, Y. / He, Y. / Ping, L. / Huang, C. / Chen, H. et al. | 2023
- 494
-
Enteropathy associated T‐cell lymphoma: a population‐based cohort study on incidence, treatment and outcome in The NetherlandsMeeuwes, F. O. / Brink, M. / Plattel, W. J. / Vermaat, J. S. P. / Kersten, M. J. / Wondergem, M. / Visser, O. / van der Poel, M. W. M. / Oostvogels, R. / Woei‐A‐Jin, F. J. S. H. et al. | 2023
- 495
-
Comparison of CHOP‐like with or without Tucidinostat in the first‐line treatment of Peripheral T‐cell lymphoma: a retrospective propensity score‐matched studyWen, X. / Yu, Q. / Wang, J. / Zheng, M. / Zhao, J. / Ma, L. / Su, L. et al. | 2023
- 496
-
Role of upfront autologous stem cell transplantation (ASCT) in adults with T‐NHL in first complete remission (CR1): A systematic literature review and meta‐analysisMichelle, P. L. / Koh, L. P. / Girard, L. / koh, Y. J. / Samuel, M. et al. | 2023
- 497
-
A randomized phase II trial of CHOP versus ICED and autologous stem cell transplantation in newly diagnosed T‐cell lymphomaYoo, K. H. / Kim, S. J. / Jo, J. / Yoon, D. H. / Yang, D. / Yoon, S. E. / Lee, G. / Park, Y. / Kang, K. / Lee, H. et al. | 2023
- 499
-
Chemoresistance in acute myeloid leukemia: An alternative single‐cell RNA sequencing approachCheng, Po‐Liang / Hsiao, Tzu‐Hung / Chen, Chung‐Hsing / Hung, Miao‐Neng / Jhan, Pei‐Pei / Lee, Li‐Wen / Wu, Ting‐Shuan / Tsai, Jia‐Rung / Teng, Chieh‐Lin Jerry et al. | 2023
- 499
-
Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histologyMehta‐Shah, N. / Jacobsen, E. D. / Zinzani, P. L. / Zain, J. / Mead, M. / Casulo, C. / Gritti, G. / Pinter‐Brown, L. / Izutsu, K. / Waters, S. et al. | 2023
- 500
-
Improved prognosis of advanced‐stage extranodal NK/T‐cell lymphoma: results of the NKEA‐Next studyFujimoto, A. / Miyazaki, K. / Taguchi, S. / Asano, N. / Yakushijin, K. / Fujino, T. / Munakata, W. / Ejima, Y. / Hirano, M. / Kubota, N. et al. | 2023
- 502
-
Efficacy of anti‐PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSAMarouf, A. / Chaubard, S. / Michot, J. / Liévin, R. / Rossignol, J. / Golfier, C. / Allangba, O. / Philippe, L. / Tessoulin, B. / Chauchet, A. et al. | 2023
- 503
-
Pegarspargase and sintilimab for newly diagnosed, advanced stage natural killer T‐cell lymphoma, nasal type: an open‐label, single‐arm, phase 2 studyXiong, J. / Cheng, S. / Wang, L. / Xu, P. / Zhao, W. et al. | 2023
- 503
-
Interim analysis of a prospective multicenter phase II study for advanced‐stage or relapsed/refractory natural killer/T cell lymphomaLiu, W. / Zhao, L. / Wu, C. / Yu, H. / Li, Z. / Liu, L. / Gao, D. / Sun, Y. / Wei, X. / Wu, Y. et al. | 2023
- 504
-
Imatinib‐induced complete and long‐term sustained remission in chemotherapy‐resistant systemic ALK‐positive anaplastic large cell lymphomaPichler, A. / Kornauth, C. / Garces‐de‐los‐Fayos‐Alonso, I. / Kazianka, L. / Alachram, H. / Zibat, A. / Pemovska, T. / Heller, G. / Greil, R. / Kenner, L. et al. | 2023
- 505
-
Brigatinib in patients with ALK‐positive anaplastic large cell lymphoma who have failed brentuximab vedotinVeleanu, L. / Tesson, B. / Lamant, L. / Marçais, A. / Bruneau, J. / Kaltenbach, S. / Brouzes, C. / Degoutte, C. / Moraly, J. / Villarese, P. et al. | 2023
- 506
-
Long‐term outcomes with mogamulizumab alone or in combination with other therapies for the treatment of cutaneous t‐cell lymphomaBojanini, L. / Herrera, M. / Li, S. / Xu, N. / Ahmed, A. A. / Khodadoust, M. / Kim, Y. H. et al. | 2023
- 508
-
Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of advanced extranodal NK/T‐cell lymphomaFu, R. / Liang, Y. / Wei, L. / Piao, Y. / Wang, L. et al. | 2023
- 509
-
Safety and efficacy of brentuximab vedotin in Chinese adults with CD30+ peripheral T‐cell lymphoma: an interim analysis from a prospective, observational, real‐world studyCai, M. / Cui, G. / Liu, L. / Li, Z. / Bai, O. / Lu, Y. / Shi, K. / Wang, J. / Zhang, W. / Zhao, W. et al. | 2023
- 510
-
Knockdown of let‐7b in leukemia associated macrophages inhibit acute myeloid leukemia progressionTian, Chen / Li, Yueyang / Si, Junqi / Kang, Junnan / Chen, Zehui / Nuermaimaiti, Rexidan / Wang, Yafei / Yu, Yong / Zhao, Zhigang / Wang, Xiaofang et al. | 2023
- 511
-
Outcomes of contemporary novel agent incorporation in relapsed/refractory PTCLTolu, S. S. / Seshadri, M. R. / Chen, Z. / Orlando, E. / Grenet, J. / Toor, R. / Sanjurjo, A. / Phillips, A. / Shore, T. / Martin, P. et al. | 2023
- 512
-
Allogeneic transplantation in T‐cell lymphoma: Lessons from the AATT studyTournilhac, O. / Altmann, B. / Friedrichs, B. / Bouabdallah, K. / Cartron, G. / Nickelsen, M. / Wulf, G. / Leclerc, M. / Vilatte, A. / Turlure, P. et al. | 2023
- 513
-
Predictors of response to radiation therapy and of progression to multiple myeloma in patients with solitary bone and extramedullary plasmacytomasFregonese, B. / Imber, B. / Lee, J. / Zhang, Z. / Toumbacaris, N. / Yahalom, J. / Hajj, C. et al. | 2023
- 515
-
Radiation in a new era of Multiple Myeloma management: Patterns of utilization, clinical, radiologic, and biochemical outcomes, and possible genomic correlates of responseDreyfuss, A. D. / Fregonese, B. / Ma, J. / Reith, S. / Cederquist, G. / Hubbeling, H. / Tringale, K. R. / Wijetunga, N A. / Usmani, S. / Hajj, C. et al. | 2023
- 515
-
SAR444245, a non‐alpha IL2, rescues chronic antigen and CAR‐driven T‐cell dysfunctionSheikh, I. / Choi, A. / Reville, P. K. / Henderson, J. / Rojas, E. / Le, C. / Okwuchi, C. / Carrio, R. / Pate, N. / Malley, K. et al. | 2023
- 517
-
Cellular dynamics and their impact on outcome in patients with mantle cell lymphoma during treatment with chimeric antigen receptor (CAR) T cellsWeiss, R. / Fernandez, C. P. / Boldt, A. / Hoffmann, S. / Krauss, S. / Bach, E. / Kirchberg, J. / Kurch, L. / Merz, M. / Metzeler, K. et al. | 2023
- 518
-
Responses after Allogeneic NK Cell Therapy for Lymphoma: correlative analysis revealed impact of host monocytes and robust T cells tumor traffickingBachanova, V. / Cao, Q. / Miller, J. / Maakaron, J. / Felices, M. / Wangen, R. / Larson, M. / Simantov, R. / Mazor, R. D. / Tilahun, A. et al. | 2023
- 519
-
The Italian CART‐SIE real life multicenter observational study on Chimeric Antigen Receptor T‐cell (CAR‐T) therapy for large B‐cell (LBCL) and mantle cell (MCL) lymphomasChiappella, A. / Dodero, A. / Ljevar, S. / Pennisi, M. / Bonifazi, F. / De Philippis, C. / Galli, E. / Di Rocco, A. / Tisi, M. C. / Cutini, I. et al. | 2023
- 520
-
3‐Year outcomes of adults with relapsed or refractory B‐cell acute lymphoblastic leukemia treated with brexu‐cel in ZUMA‐3 by age, prior therapies, and subsequent transplantShah, B. D. / Cassaday, R. D. / Park, J. H. / Houot, R. / Oluwole, O. O. / Logan, A. C. / Boissel, N. / Leguay, T. / Bishop, M. R. / Topp, M. S. et al. | 2023
- 520
-
Capitalizing on paradoxical activation of the mitogen‐activated protein kinase pathway for treatment of Imatinib‐resistant mast cell leukemiaWilhelm, Thomas / Toledo, Marcelo A. S. / Simons, Ilka / Stuth, Christian / Mohta, Vrinda / Mülfarth, Ronja / Nitsche, Marcus / Maschke‐Neuß, Karin / Schmitz, Susanne / Kaiser, Anne et al. | 2023
- 522
-
Matching‐adjusted indirect comparison of axicabtagene ciloleucel versus mosunetuzumab in relapsed/refractory follicular lymphoma patients after 2 prior systemic treatmentsRay, M. D. / Kanters, S. / Beygi, S. / Best, T. / Wulff, J. / Limbrick‐Oldfield, E. H. / Patel, A. R. / Oluwole, O. O. et al. | 2023
- 523
-
Outcomes in patients with EBV+ PTLD treated with allogeneic EBV‐specific T‐cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in EuropeChoquet, S. / Clark, A. / Renard, C. / Uttenthal, B. / Chaganti, S. / Trappe, R. U. / Comoli, P. / Duan, X. / Xing, B. / Wu, C. et al. | 2023
- 524
-
Combined autologous CD30.CAR‐T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study)Ahmed, S. / Mei, M. / Kurtz, D. M. / Beitinjaneh, A. / Grover, N. S. / Ramos, C. A. / Chabon, J. J. / Schultz, A. / Ding, C. / Myo, A. et al. | 2023
- 526
-
First in human data of NKX019, an allogeneic CAR NK for the treatment of relapsed/refractory (R/R) B‐cell malignanciesDickinson, M. / Hamad, N. / Bryant, C. E. / Kothari, N. / Ojeras, P. / Vohra, A. / Lin, M. / Tohme, M. / Trager, J. / Shook, D. et al. | 2023
- 527
-
A Phase I Study of CD19‐targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B‐cell LymphomaPalomba, M. L. / Riviere, I. / Sikder, D. S. / Senechal, B. / Wang, X. / Cathcart, E. R. / Liotta, K. / Li, J. / Sellner, L. / Sadelain, M. et al. | 2023
- 528
-
Outcomes with bendamustine lymphodepletion and brexucabtagene autoleucel for mantle cell lymphomaChong, E. A. / Gerson, J. N. / Nasta, S. D. / Landsburg, D. J. / Barta, S. K. / Svoboda, J. / Weber, E. / Ghilardi, G. / Ruella, M. / Porter, D. L. et al. | 2023
- 529
-
Reasons for Discordance Among Imaging‐based Response Criteria In Lymphoma Patients Receiving CAR T‐cell TherapyWinkelmann, M. / Blumenberg, V. / Rejeski, K. / Buecklein, V. / Schmidt, C. / Dekorsy, F. / Bartenstein, P. / Ricke, J. / von Bergwelt‐Baildon, M. / Subklewe, M. et al. | 2023
- 530
-
CNS radiotherapy as bridging prior to CAR T‐cell therapy for hematologic malignanciesCederquist, G. / Hubbeling, H. / Tringale, K. / Shah, G. / Tomas, A. Alarcon / Shouval, R. / Hajj, C. / Fregonese, B. / Lee, J. / Dahi, P. B. et al. | 2023
- 532
-
Multicenter experience with radiotherapy for relapse after chimeric antigen receptor T cell therapy in non‐Hodgkin lymphomaHubbeling, H. / Figura, N. / Ladbury, C. / Keit, E. R. / Chew, J. / Fregonese, B. / Silverman, E. A. / Hajj, C. / Shah, G. / Kambhampati, S. et al. | 2023
- 532
-
Developing CAR‐T‐sparing Radiotherapy ‐ early dosimetric resultsMikhaeel, N. G. / Ntentas, G. / Sivabalasingham, S. / Brady, J. L. / Tait, J. / De Farias, M. Correia / Roddie, C. / Sanderson, R. / Kuhnl, A. et al. | 2023
- 534
-
Predicting ICANS by means of plasma CAR‐T cell derived extracellular vesicles in patients undergoing infusion of anti‐CD19 CAR‐T cellsDe Felice, F. / Storci, G. / Ricci, F. / Tazzari, P. L. / De Matteis, S. / Bertuccio, S. N. / Rossini, L. / Tomassini, E. / Dicataldo, M. / Laprovitera, N. et al. | 2023
- 534
-
Transfusion needs after CD19 CAR T‐cells for large B‐cell lymphoma: predictive factors and impact on outcome. A DESCAR‐T study.Vic, S. / Thibert, J. / Bachy, E. / Cartron, G. / Gastinne, T. / Morschhauser, F. / Le Bras, F. / Bouabdallah, K. / Despas, F. / Bay, J. et al. | 2023
- 535
-
Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working groupYanagisawa, Ryu / Tamaki, Masaharu / Tanoshima, Reo / Misaki, Yukiko / Uchida, Naoyuki / Koi, Satoshi / Tanaka, Takashi / Ozawa, Yukiyasu / Matsuo, Yayoi / Tanaka, Masatsugu et al. | 2023
- 536
-
Neurotoxicity in patients with CNS lymphomas treated with CAR‐T cell therapy. A LOC network studyTost, H. Hernandez / Weiss, N. / Choquet, S. / Ribeiro, M. / Birzu, C. / Le Guennec, L. / Shor, N. / Morel, V. / Solorzano, S. / Souchet, L. et al. | 2023
- 537
-
Factors Associated with Increased Risk of Major Cardiovascular Events for Patients Undergoing CAR T TherapyReves, H. / Eljalby, M. / Rao, A. / Chandra, A. / Zhang, K. / Muquith, M. / Jackson, M. / Geethakumari, P. Ramakrishnan / Afrough, A. / Anderson, L. D. Jr. et al. | 2023
- 538
-
Health‐related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso‐cel in TRANSCEND CLL 004Maloney, D. G. / Siddiqi, T. / Fakhri, B. / Ma, S. / Shah, N. N. / Riedell, P. A. / Schuster, S. J. / Eliason, L. / Wang, L. / Tuazon, S. A. et al. | 2023
- 541
-
‘Don’t keep me waiting’: estimating the impact on lifetime survival and QALYs of reduced vein‐to‐vein time for LBCL patients treated with CAR T in the 3L+ settingMaziarz, R. / Vadgama, S. / Pasquini, M. / Hu, Z. / Ray, M. / Smith, H. / Bullement, A. / Edmondson‐Jones, M. / Sullivan, W. / Cartron, G. et al. | 2023
- 542
-
Remote monitoring of CAR T‐cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA programColin, F. / Bellec, A. / Le Bars, L. / Granger, M. / De Guibert, S. / Manson, G. / Lhomme, F. / Marchand, T. / Mear, J. / Barbe, M. Escoffre et al. | 2023
- 542
-
Drug‐resistance mutations in BTK occur in distinct enzymatic classes and are overcome by BTK degradationMontoya, S. / Bourcie, J. / Sondhi, A. / Jahn, J. / Alencar, A. / Abdel‐Wahab, O. / Taylor, J. et al. | 2023
- 544
-
BTM 3566, a Novel Activator of the Mitochondrial Stress Response Induces Robust Therapeutic Responses in Diffuse Large B‐cell Lymphoma in vitro and in vivoBashir, Z. / Schwarzer, A. / Oliveria, M. / Kleppa, M. / Anantha, A. / Kostura, M. / Stocum, M. / Hembrough, T. et al. | 2023
- 544
-
MALT1 protease inhibition overcomes BTK inhibitor resistance and shows synergistic activity with venetoclax in models of B cell lymphoma and leukemiaPlotnik, J. / Bontcheva1, V. / Dowell, C. / Chen, J. / Richardson, A. / McClure, R. / Jung, P. / Pham, L. / Souers, A. / Meulbroek, J. et al. | 2023
- 546
-
Diffuse large B‐cell lymphoma cell‐cycle progression requires the cyclin‐G associated kinase (GAK), a novel drug target from machine learning‐enabled phenotypic screeningLightfuss, O. B. / Newsam, A. / Kumar, P. / Li, L. / Ghoshal, A. / Alaoui, A. Y. / Schürer, S. / Lemmon, V. / Maura, F. / Feng, Y. et al. | 2023
- 546
-
BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient‐Derived ModelsMa, J. / Lu, M. / Chen, L. / Geng, H. / Kumar, A. / Noviski, M. / Rountree, R. / Guiducci, C. / Rubenstein, J. et al. | 2023
- 546
-
15‐days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high‐risk myelodysplastic syndromes: A retrospective single‐center studyMei, Chen / Ye, Li / Ren, Yanling / Zhou, Xinping / Ma, Liya / Xu, Gaixiang / Xu, Weilai / Lu, Chenxi / Yang, Haiyang / Luo, Yingwan et al. | 2023
- 547
-
Differential ibrutinib sensitivity in Cd79b‐mutant and wildtype subtypes of a novel Myd88‐driven DLBCL mouse modelFlümann, R. / Hansen, J. / Klein, S. / Goldfarb‐Wittkopf, H. / Pfeiffer, P. / Wirtz, J. / Lütz, A. F. / Persigehl, T. / Büttner, R. / Jachimowicz, R. et al. | 2023